

Measurement of C-Reactive Protein for the Targeting of Prevention of Acute Coronary Events

New England Journal of Medicine

344, 1959-1965

DOI: [10.1056/nejm200106283442601](https://doi.org/10.1056/nejm200106283442601)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Oversight Hearings Promote NSF Insight. <i>BioScience</i> , 1979, 29, 433-434.	2.2	0
2	Statins: can CRP levels determine coronary risk?. <i>Inpharma Weekly</i> , 2001, &NA;, 12.	0.0	0
3	Acute coronary syndrome without ST elevation: implementation of new guidelines. <i>Lancet, The</i> , 2001, 358, 1533-1538.	6.3	114
4	From the World Literature. <i>American Journal of Cardiovascular Drugs</i> , 2001, 1, 305-313.	1.0	0
5	Opportunities for the treatment of inflammation in cardiovascular disease. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 1751-1763.	0.9	1
6	Statins in the 21st century: end of the simple story?. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1755-1766.	1.9	22
7	Cholesterol Lowering Therapy in Coronary Artery Disease: With Particular Reference to Statins. <i>Sunhwan'gi</i> , 2001, 31, 849.	0.3	6
8	Issues surrounding age: vascular disease in the elderly. <i>Current Opinion in Lipidology</i> , 2001, 12, 601-609.	1.2	29
9	Systemic Inflammation as a Cardiovascular Disease Risk Factor and as a Potential Target for Drug Therapy. <i>Heart Disease (Hagerstown, Md)</i> , 2001, 3, 326-332.	1.3	57
10	Inflammation and Atherosclerosis. <i>Pathology Patterns Reviews</i> , 2001, 116, S108-S115.	0.4	53
11	Nutrition and therapeutics. <i>Current Opinion in Lipidology</i> , 2001, 12, 659-661.	1.2	0
14	Statines et rejet de greffe : au-delÃ du cholestÃ©rol, l'immunitÃ©. <i>Revue Francaise Des Laboratoires</i> , 2001, 10.	0.0	0
15	Cytokines as new treatment targets in chronic heart failure. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2001, 2, 271.	1.5	39
17	Novel Clinical Markers of Vascular Wall Inflammation. <i>Circulation Research</i> , 2001, 89, 763-771.	2.0	663
18	Atherosclerosis and connective tissue diseases. <i>Joint Bone Spine</i> , 2001, 68, 564-575.	0.8	32
19	Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. <i>European Heart Journal</i> , 2001, 22, 2135-2137.	1.0	47
20	Cardiac protection by pharmacological modulation of inflammation. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 1913-1924.	1.9	3
21	Inflammatory Markers in Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2154.	3.8	39

#	ARTICLE	IF	CITATIONS
22	Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1712-1719.	1.1	1,182
23	Ecology in Evolution. <i>New England Journal of Medicine</i> , 2001, 344, 2018-2020.	13.9	6
24	Locking a Leukocyte Integrin with Statins. <i>New England Journal of Medicine</i> , 2001, 345, 1419-1421.	13.9	64
25	Statins and the Acute-Phase Response. <i>New England Journal of Medicine</i> , 2001, 344, 2016-2018.	13.9	144
26	The Antiinflammatory Effects of Statins. <i>New England Journal of Medicine</i> , 2001, 345, 1209-1211.	13.9	8
27	Hyperglycemia-induced Production of Acute Phase Reactants in Adipose Tissue. <i>Journal of Biological Chemistry</i> , 2001, 276, 42077-42083.	1.6	230
28	Physical exercise in dyslipoproteinemias: An update. <i>European Journal of Sport Science</i> , 2002, 2, 1-13.	1.4	3
29	Simvastatin Lowers C-Reactive Protein Within 14 Days. <i>Circulation</i> , 2002, 106, 1447-1452.	1.6	336
30	Adiposity and Diabetes. <i>Diabetes Care</i> , 2002, 25, 2342-2349.	4.3	24
31	Statins and Renal Function. <i>Angiology</i> , 2002, 53, 493-502.	0.8	95
32	Novel Insights into Uremic Vascular Calcification: Role of Matrix Gla Protein and Alpha-2-Heremans Schmid Glycoprotein/Fetuin. <i>Blood Purification</i> , 2002, 20, 473-476.	0.9	55
33	Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events. <i>New England Journal of Medicine</i> , 2002, 347, 1557-1565.	13.9	3,201
34	High Sensitivity C-reactive Protein: An Emerging Role in Cardiovascular Risk Assessment. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2002, 39, 459-497.	2.7	49
35	Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy. <i>Stroke</i> , 2002, 33, 862-875.	1.0	205
36	Statins: balancing benefits, efficacy and safety. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 469-477.	0.9	10
37	Role of Infectious and Immune Factors in Coronary and Cerebrovascular Arteriosclerosis. <i>Vaccine Journal</i> , 2002, 9, 207-215.	3.2	19
38	Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1662-1667.	1.1	217
39	Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels. <i>Angiology</i> , 2002, 53, 273-277.	0.8	50

#	ARTICLE	IF	CITATIONS
40	Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1194-1199.	1.1	340
41	Is High-Sensitivity C-Reactive Protein an Effective Screening Test for Cardiovascular Risk?. <i>Archives of Internal Medicine</i> , 2002, 162, 867.	4.3	53
42	Need to Test the Arterial Inflammation Hypothesis. <i>Circulation</i> , 2002, 106, 136-140.	1.6	137
43	Tumour necrosis factor- α , inflammatory biomarkers, and atherogenesis. <i>European Heart Journal</i> , 2002, 23, 345-347.	1.0	23
44	Why some patients respond poorly to statins and how this might be remedied. <i>European Heart Journal</i> , 2002, 23, 200-206.	1.0	53
45	Is C-reactive protein an additional, surrogate end-point for statin treatment?. <i>European Heart Journal</i> , 2002, 23, 761-764.	1.0	8
46	Is time the overriding factor in thrombolytic therapy?. <i>European Heart Journal</i> , 2002, 23, 347-349.	1.0	0
47	Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. <i>Cardiovascular Research</i> , 2002, 53, 1029-1034.	1.8	227
48	Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond. <i>Current Medicinal Chemistry</i> , 2002, 9, 1831-1850.	1.2	54
49	Use of Statins and Aspirin to Reduce Risks of Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2002, 7, 77-80.	1.0	22
50	C-Reactive Protein α To Screen or Not to Screen?. <i>New England Journal of Medicine</i> , 2002, 347, 1615-1617.	13.9	128
51	Einsatz der Statine in der Neurologie. <i>Aktuelle Neurologie</i> , 2002, 29, 254-261.	0.1	4
52	Diabetes and Atherothrombotic Disease: Linked through Inflammation?. <i>Seminars in Vascular Medicine</i> , 2002, 2, 067-074.	2.1	4
53	C-Reactive protein augments inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. <i>Cardiovascular Research</i> , 2002, 56, 86-92.	1.8	40
54	Acute-Phase Reactants and Coronary Heart Disease. <i>Seminars in Vascular Medicine</i> , 2002, 02, 417-428.	2.1	29
55	The Need for Risk Factor Assessment in Atherothrombotic Vascular Disease. <i>Seminars in Vascular Medicine</i> , 2002, 02, 231-232.	2.1	2
56	Associations Between Cardiorespiratory Fitness and C-Reactive Protein in Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1869-1876.	1.1	308
57	A Simple Biomarker to Exclude the Presence of Low Grade Inflammation in Apparently Healthy Individuals. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 281-286.	3.1	6

#	ARTICLE	IF	CITATIONS
58	Statin Therapy in Acute Coronary Syndromes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1524-1534.	1.1	146
60	Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease. <i>Circulation</i> , 2002, 105, 800-803.	1.6	130
61	Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events. <i>Circulation</i> , 2002, 105, 1776-1779.	1.6	58
62	Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women. <i>Circulation</i> , 2002, 105, 1531-1533.	1.6	79
63	Statin Therapy. <i>Circulation</i> , 2002, 105, 2937-2938.	1.6	41
64	Evidence-Based Risk Stratification to Target Therapies in Acute Coronary Syndromes. <i>Circulation</i> , 2002, 106, 1588-1591.	1.6	54
65	Causal Structures for Evaluating Statin Class Effects. <i>Annals of Pharmacotherapy</i> , 2002, 36, 1961-1965.	0.9	1
66	Inflammatory Biomarkers, Statins, and the Risk of Stroke. <i>Circulation</i> , 2002, 105, 2583-2585.	1.6	54
67	Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 980.	3.8	582
68	Role of Infection in Atherosclerosis and Coronary Artery Disease: A New Therapeutic Target?. <i>Cardiology in Review</i> , 2002, 10, 199-210.	0.6	24
69	C-Reactive Protein Predicts Progression of Atherosclerosis Measured at Various Sites in the Arterial Tree. <i>Stroke</i> , 2002, 33, 2750-2755.	1.0	178
70	Role of Inflammation and Its Treatment in ESRD Patients. <i>Blood Purification</i> , 2002, 20, 70-80.	0.9	43
71	C-reactive protein and prognosis after percutaneous coronary intervention. <i>European Heart Journal</i> , 2002, 23, 923-925.	1.0	16
72	The Surveillance of Cholesterol Management in the Cardiac Rehabilitation Setting. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2002, 22, 245-250.	0.5	3
73	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2002, 13, 109-111.	1.2	1
74	Ethical Considerations in Image-Based Screening for Coronary Artery Disease. <i>Topics in Magnetic Resonance Imaging</i> , 2002, 13, 95-106.	0.7	2
75	Relationship of C-reactive protein to presence and severity of coronary atherosclerosis in patients with stable angina pectoris or a pathological exercise test. <i>Coronary Artery Disease</i> , 2002, 13, 151-154.	0.3	31
76	High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease. <i>Current Opinion in Cardiology</i> , 2002, 17, 325-331.	0.8	48

#	ARTICLE	IF	CITATIONS
77	The regulation of ischemic acute renal failure by extrarenal organs. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 451-457.	1.0	39
78	Hyperlipidaemia and cardiovascular disease: C-reactive protein and atherosclerosis - new dimensions. <i>Current Opinion in Lipidology</i> , 2002, 13, 101-103.	1.2	2
79	Inflammatory markers and coronary heart disease. <i>Current Opinion in Lipidology</i> , 2002, 13, 383-389.	1.2	91
80	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 281-286.	1.5	9
81	Statins and stroke: evidence for cholesterol-independent effects. <i>European Heart Journal</i> , 2002, 23, 1908-1921.	1.0	77
82	Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. <i>Clinical Science</i> , 2002, 103, 303-310.	1.8	25
83	Long-Term Effects of Inflammation-Sensitive Plasma Proteins and Systolic Blood Pressure on Incidence of Stroke. <i>Stroke</i> , 2002, 33, 2744-2749.	1.0	84
84	Do atherosclerosis and type 2 diabetes share a common inflammatory basis?. <i>European Heart Journal</i> , 2002, 23, 831-834.	1.0	172
85	Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. <i>American Journal of Medicine</i> , 2002, 112, 126-134.	0.6	49
86	Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. <i>American Journal of Medicine</i> , 2002, 112, 275-280.	0.6	148
87	Effects of hormone replacement therapy on C-reactive protein levels in healthy postmenopausal women: comparison between oral and transdermal administration of estrogen. <i>American Journal of Medicine</i> , 2002, 113, 331-334.	0.6	34
88	The Importance of Lipid Evaluation and Management in the Prevention and Treatment of Acute Myocardial Infarction. <i>Preventive Cardiology</i> , 2002, 5, 131-137.	1.1	1
89	C-Reactive Protein, Statins, and the Primary Prevention of Atherosclerotic Cardiovascular Disease. <i>Preventive Cardiology</i> , 2002, 5, 42-46.	1.1	18
90	Statins and C-Reactive Protein: Considering a Novel Marker of Cardiovascular Risk. <i>Preventive Cardiology</i> , 2002, 5, 200-203.	1.1	11
91	C-REACTIVE PROTEIN LEVELS ARE INFLUENCED BY COMMON IL-1 GENE VARIATIONS. <i>Cytokine</i> , 2002, 17, 171-174.	1.4	109
92	High coronary artery calcium scores pose an extremely elevated risk for hard events. <i>Journal of the American College of Cardiology</i> , 2002, 39, 225-230.	1.2	293
93	C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. <i>Journal of the American College of Cardiology</i> , 2002, 39, 632-637.	1.2	206
94	Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels. <i>Journal of the American College of Cardiology</i> , 2002, 40, 49-55.	1.2	41

#	ARTICLE	IF	CITATIONS
95	The erythrocyte adhesiveness/aggregation test (EAAT). <i>Atherosclerosis</i> , 2002, 165, 343-351.	0.4	32
96	Statins and Menopause. <i>Drugs</i> , 2002, 62, 2421-2431.	4.9	6
97	Exercise Decreases Plasma Total Homocysteine in Overweight Young Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 4496-4501.	1.8	169
98	How Do HMG-CoA Reductase Inhibitors Prevent Stroke?. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 7-14.	1.0	10
99	Effects of preventive group education on the resistance of LDL against oxidation and risk factors for coronary heart disease in bypass surgery patients. <i>Annals of Medicine</i> , 2002, 34, 272-283.	1.5	5
100	Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. <i>Lancet, The</i> , 2002, 359, 2159-2163.	6.3	235
101	C-reactive protein, arterial endothelial activation, and development of transplant coronary artery disease: a prospective study. <i>Lancet, The</i> , 2002, 360, 1462-1467.	6.3	104
102	MRC/BHF Heart Protection Study. <i>Lancet, The</i> , 2002, 360, 1780.	6.3	4
103	C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. <i>Clinica Chimica Acta</i> , 2002, 317, 1-15.	0.5	125
104	The spectrum of long-term renal transplantation: Outcomes, complications, and clinical studies. <i>Transplantation Reviews</i> , 2002, 16, 22-50.	1.2	9
105	C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. <i>American Heart Journal</i> , 2002, 144, 233-238.	1.2	194
106	C-reactive protein: history and revival. <i>European Journal of Internal Medicine</i> , 2002, 13, 412-422.	1.0	135
107	Statins as anti-inflammatory agents. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 482-487.	4.0	305
108	Influence of HMG-CoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. <i>International Journal of Cardiology</i> , 2002, 82, 25-31.	0.8	73
109	Effects of lipids on thrombotic mechanisms in atherosclerosis. <i>International Journal of Cardiology</i> , 2002, 86, 239-247.	0.8	13
110	Inflammation and Atherosclerosis. <i>Circulation</i> , 2002, 105, 1135-1143.	1.6	6,191
111	Pharmacologic therapy for peripheral arterial disease and claudication. <i>Journal of Vascular Surgery</i> , 2002, 36, 1283-1291.	0.6	73
112	Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1085-1092.	1.4	43

#	ARTICLE	IF	CITATIONS
113	Cardiovascular disease prevention. Primary Care - Clinics in Office Practice, 2002, 29, 667-696.	0.7	6
115	Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis, 2002, 165, 361-366.	0.4	111
116	New Tools for Coronary Risk Assessment. Circulation, 2002, 105, 886-892.	1.6	184
117	Role of Inflammation on Coronary Artery Disease in Koreans. Sunhwan'gi, 2002, 32, 988.	0.3	6
118	Prediction of cardiovascular risk using soluble cell adhesion molecules. European Heart Journal, 2002, 23, 1569-1574.	1.0	75
119	Atherosclerosis or Atheroscleritis: What's in a Name?. Cardiology, 2002, 98, 111-112.	0.6	2
120	Management of Stable Angina and Unstable Angina/Non-ST-elevation Myocardial Infarction. Medicine, 2002, 30, 64-70.	0.2	0
121	Dyslipidemia and the vulnerable plaque. Progress in Cardiovascular Diseases, 2002, 44, 415-428.	1.6	28
122	Role of Inflammation in Cardiovascular Disease: How to Use C-reactive Protein in Clinical Practice. Progress in Cardiovascular Nursing, 2002, 17, 174-185.	0.5	16
123	Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. American Journal of Cardiology, 2002, 89, 468-469.	0.7	9
124	Implications of 2001 cholesterol treatment guidelines based on a retrospective analysis of a high-risk patient cohort. American Journal of Cardiology, 2002, 89, 765-766.	0.7	2
125	Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) TIMI 22 trial. American Journal of Cardiology, 2002, 89, 860-861.	0.7	118
126	Effect of cocaine usage on C-reactive protein, von Willebrand factor, and fibrinogen. American Journal of Cardiology, 2002, 89, 1133-1135.	0.7	61
127	Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. American Journal of Cardiology, 2002, 89, 1205-1207.	0.7	84
128	Effects of statins on six-month survival and clinical restenosis frequency after coronary stent deployment. American Journal of Cardiology, 2002, 90, 299-302.	0.7	19
129	Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary artery disease. American Journal of Cardiology, 2002, 90, 784-786.	0.7	31
130	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. American Journal of Cardiology, 2002, 90, 11-21.	0.7	267
131	Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients. American Journal of Cardiology, 2002, 90, 942-946.	0.7	37

#	ARTICLE	IF	CITATIONS
132	Sensitive markers of inflammation make it possible to study the chronic process: the rise of interest in low levels of C-reactive protein. <i>Vascular Pharmacology</i> , 2002, 39, 99-104.	1.0	38
133	Patient survival after renal transplantation III: The effects of statins. <i>American Journal of Kidney Diseases</i> , 2002, 40, 638-643.	2.1	99
134	Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. <i>Journal of Diabetes and Its Complications</i> , 2002, 16, 382-385.	1.2	19
135	The role of inflammation and infection in coronary artery disease: a clinical perspective. <i>ACC Current Journal Review</i> , 2002, 11, 32-34.	0.1	12
136	Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. <i>Experimental Gerontology</i> , 2002, 37, 925-929.	1.2	27
137	Vascular inflammation as a therapeutic target for prevention of cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2002, 4, 77-81.	2.0	8
138	Atherosclerosis and inflammation. <i>Current Atherosclerosis Reports</i> , 2002, 4, 92-98.	2.0	39
139	Goals of statin therapy: Three viewpoints. <i>Current Atherosclerosis Reports</i> , 2002, 4, 26-33.	2.0	5
140	Statins and inflammatory markers. <i>Current Atherosclerosis Reports</i> , 2002, 4, 42-47.	2.0	20
141	Early use of statins in acute coronary syndromes. <i>Current Cardiology Reports</i> , 2002, 4, 289-297.	1.3	2
142	Statins: the new aspirin?. <i>Cellular and Molecular Life Sciences</i> , 2002, 59, 1771-1786.	2.4	86
144	Pleiotropic effects of HMG-CoA reductase inhibitors. <i>Basic Research in Cardiology</i> , 2002, 97, 105-116.	2.5	187
145	Inflammatory bio-markers and cardiovascular risk prediction. <i>Journal of Internal Medicine</i> , 2002, 252, 283-294.	2.7	583
146	Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. <i>Kidney International</i> , 2002, 61, S5-S10.	2.6	16
147	Do AV Fistulas Contribute to Cardiac Mortality in Hemodialysis Patients?. <i>Seminars in Dialysis</i> , 2002, 15, 14-17.	0.7	48
148	DIALYZING THE ELDERLY: ISSUES AND CONCERNS: Cardiovascular Abnormalities and Hypertension in the Elderly Dialysis Patient. <i>Seminars in Dialysis</i> , 2002, 15, 121-126.	0.7	2
149	Congestive Heart Failure Due to Systolic Dysfunction: The Cinderella of Cardiovascular Management in Dialysis Patients. <i>Seminars in Dialysis</i> , 2002, 15, 135-140.	0.7	31
150	Are early clinical effects of cholesterol lowering mediated through effects on inflammation?. <i>Acta Physiologica Scandinavica</i> , 2002, 176, 147-150.	2.3	15

#	ARTICLE	IF	CITATIONS
151	The potential for novel anti-inflammatory therapies for coronary artery disease. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 122-130.	21.5	29
152	C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. <i>Journal of Nutritional Biochemistry</i> , 2002, 13, 316-321.	1.9	66
153	Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 1323-1328.	1.1	281
154	Inflammatory predictors of mortality in the scandinavian simvastatin survival study. <i>Clinical Cardiology</i> , 2002, 25, 461-466.	0.7	34
155	Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. <i>Diabetologia</i> , 2002, 45, 1609-1616.	2.9	113
156	Anti-Inflammatory and Immunomodulating Properties of Statins: An Additional Tool for the Therapeutic Approach of Systemic Autoimmune Diseases?. <i>Clinical Reviews in Allergy and Immunology</i> , 2002, 23, 263-278.	2.9	29
157	Hormone Therapies and Vascular Outcomes: Who is at Risk?. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 87-90.	1.0	6
158	Title is missing!. <i>Molecular and Cellular Biochemistry</i> , 2003, 246, 45-50.	1.4	22
159	Variations in binding characteristics of glycosylated human C-reactive proteins in different pathological conditions. <i>Glycoconjugate Journal</i> , 2003, 20, 537-543.	1.4	31
160	Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. <i>Heart Failure Reviews</i> , 2003, 8, 71-86.	1.7	132
161	Effects of statins in reducing thrombotic risk and modulating plaque vulnerability. <i>Clinical Cardiology</i> , 2003, 26, 11-14.	0.7	45
162	Comparing HMG-CoA reductase inhibitors. <i>Clinical Cardiology</i> , 2003, 26, 15-20.	0.7	18
163	Risks and benefits of continued aggressive statin therapy. <i>Clinical Cardiology</i> , 2003, 26, 3-12.	0.7	27
164	Connecting the role of C-reactive protein and statins in cardiovascular disease. <i>Clinical Cardiology</i> , 2003, 26, 39-44.	0.7	43
165	Inflammation and Infections as Risk Factors for Ischemic Stroke. <i>Stroke</i> , 2003, 34, 2518-2532.	1.0	451
166	Gender, hyperlipidemia, and coronary artery disease. <i>Comprehensive Therapy</i> , 2003, 29, 7-17.	0.2	2
167	C-reactive protein and risk of cardiovascular disease: Evidence and clinical application. <i>Current Atherosclerosis Reports</i> , 2003, 5, 341-349.	2.0	93
168	Isoprenoid metabolism and the pleiotropic effects of statins. <i>Current Atherosclerosis Reports</i> , 2003, 5, 372-378.	2.0	84

#	ARTICLE	IF	CITATIONS
169	Early use of statins in acute coronary syndromes. <i>Current Atherosclerosis Reports</i> , 2003, 5, 44-51.	2.0	10
170	C-reactive protein: The pawn has been promoted to queen. <i>Current Atherosclerosis Reports</i> , 2003, 5, 101-105.	2.0	29
171	Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 2679-2691.	2.4	43
173	Inflammatory mediators and islet β -cell failure: a link between type 1 and type 2 diabetes. <i>Journal of Molecular Medicine</i> , 2003, 81, 455-470.	1.7	379
174	Amino acid and protein oxidation in cardiovascular disease. <i>Amino Acids</i> , 2003, 25, 365-374.	1.2	54
175	Understanding and managing cancer cachexia. <i>Journal of the American College of Surgeons</i> , 2003, 197, 143-161.	0.2	175
177	Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. <i>American Journal of Kidney Diseases</i> , 2003, 42, 256-263.	2.1	58
178	Statin rebound effect?. <i>Translational Research</i> , 2003, 141, 235-236.	2.4	4
179	Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection. <i>American Journal of Cardiology</i> , 2003, 92, 1224-1227.	0.7	19
180	Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. <i>American Journal of Cardiology</i> , 2003, 92, 1287-1293.	0.7	96
181	Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. <i>American Journal of Cardiology</i> , 2003, 92, 1414-1418.	0.7	125
182	Role of C-reactive protein in the assessment of cardiovascular risk. <i>American Journal of Cardiology</i> , 2003, 91, 200-202.	0.7	43
183	Mechanisms of plaque stabilization with statins. <i>American Journal of Cardiology</i> , 2003, 91, 4-8.	0.7	188
184	Utility of inflammatory markers in the management of coronary artery disease. <i>American Journal of Cardiology</i> , 2003, 92, 10-18.	0.7	68
185	A practical approach to risk assessment to prevent coronary artery disease and its complications. <i>American Journal of Cardiology</i> , 2003, 92, 19-26.	0.7	72
186	Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 92, 298-301.	0.7	56
187	Frequency of and outcome of acute coronary syndromes in patients with human immunodeficiency virus infection. <i>American Journal of Cardiology</i> , 2003, 92, 301-303.	0.7	34
188	High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. <i>American Journal of Cardiology</i> , 2003, 92, 17-22.	0.7	207

#	ARTICLE	IF	CITATIONS
189	Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. <i>Arthritis and Rheumatism</i> , 2003, 48, 81-89.	6.7	183
190	Coronary artery disease - more disease, more patients, better treatment. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 1-4.	0.7	3
191	Anti-inflammatory and immunomodulatory effects of statins. <i>Kidney International</i> , 2003, 63, 12-23.	2.6	279
192	C-reactive protein is associated with renal function abnormalities in a non-diabetic population. <i>Kidney International</i> , 2003, 63, 654-661.	2.6	208
193	Uremia-associated immune defect: The IL-10/CRP axis. <i>Kidney International</i> , 2003, 63, S76-S79.	2.6	37
194	Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. <i>Kidney International</i> , 2003, 63, S84-S87.	2.6	99
195	Update on C-reactive protein as a risk marker in cardiovascular disease. <i>Kidney International</i> , 2003, 63, S58-S61.	2.6	32
196	Traditional and emerging cardiovascular risk factors in end-stage renal disease. <i>Kidney International</i> , 2003, 63, S105-S110.	2.6	168
197	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Renal Transplant Recipients. <i>Seminars in Dialysis</i> , 2003, 16, 106-110.	0.7	43
198	Changes in C-reactive Protein Plasma Levels During Low-density Lipoprotein Apheresis. <i>Therapeutic Apheresis and Dialysis</i> , 2003, 7, 431-434.	0.4	32
200	Prediction of cardiovascular risk in people with diabetes. <i>Diabetic Medicine</i> , 2003, 20, 515-527.	1.2	29
202	Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. <i>International Journal of Obesity</i> , 2003, 27, S29-S34.	1.6	116
204	Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. <i>Clínica e Investigación en Arteriosclerosis</i> , 2003, 15, 171-173.	0.4	0
205	Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. <i>Journal of Vascular Surgery</i> , 2003, 38, 374-379.	0.6	157
206	Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus 11Competition of interest: none.. <i>Journal of Vascular Surgery</i> , 2003, 38, 111-115.	0.6	16
207	Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. <i>Atherosclerosis</i> , 2003, 169, 317-321.	0.4	57
208	Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. <i>Atherosclerosis</i> , 2003, 170, 261-267.	0.4	60
209	Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: The PRIME Study. <i>Atherosclerosis</i> , 2003, 170, 169-176.	0.4	156

#	ARTICLE	IF	CITATIONS
210	Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. <i>Atherosclerosis</i> , 2003, 170, 315-323.	0.4	132
211	C-reactive protein and other inflammatory risk markers in acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, S37-S42.	1.2	299
212	The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. <i>Journal of the American College of Cardiology</i> , 2003, 42, 211-216.	1.2	248
213	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	3.1	52
214	C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1255-1261.	1.1	348
215	Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions. <i>Circulation</i> , 2003, 107, 1750-1756.	1.6	195
216	Reduction of C-reactive protein levels through use of a multivitamin. <i>American Journal of Medicine</i> , 2003, 115, 702-707.	0.6	59
217	Endothelial function, inflammation, and prognosis in cardiovascular disease. <i>American Journal of Medicine</i> , 2003, 115, 99-106.	0.6	212
218	Prediction of Recurrent Events by D-Dimer and Inflammatory Markers in Patients with Normal Cardiac Troponin I (PREDICT) study. <i>American Heart Journal</i> , 2003, 145, 986-992.	1.2	45
219	Arterial compliance adds to conventional risk factors for prediction of angiographic coronary artery disease. <i>American Heart Journal</i> , 2003, 146, 662-667.	1.2	40
220	The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. <i>American Journal of Medicine</i> , 2003, 114, 199-205.	0.6	82
221	Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. <i>American Journal of Medicine</i> , 2003, 114, 485-494.	0.6	44
222	Is inflammation the critical factor linking vulnerable coronary plaques to clinical coronary disease?. <i>American Journal of Medicine</i> , 2003, 114, 607-608.	0.6	0
223	Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. <i>Circulation</i> , 2003, 107, 363-369.	1.6	2,100
224	C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events. <i>Circulation</i> , 2003, 107, 391-397.	1.6	2,145
225	Old and new cardiovascular risk factors: from unresolved issues to new opportunities. <i>Atherosclerosis Supplements</i> , 2003, 4, 5-17.	1.2	31
226	Markers of Inflammation and Cardiovascular Disease. <i>Circulation</i> , 2003, 107, 499-511.	1.6	5,405
227	The PROSPER trial. <i>Lancet</i> , The, 2003, 361, 427.	6.3	1

#	ARTICLE	IF	CITATIONS
228	The PROSPER trial. <i>Lancet</i> , The, 2003, 361, 428.	6.3	3
229	Evaluation of a modified hsCRP method for point-of-service testing. <i>Clinica Chimica Acta</i> , 2003, 334, 249-252.	0.5	2
230	Reduction of serum C-reactive protein by statin therapy may reflect decreased isoprenylation of Rac-1, a mediator of the IL-6 signal transduction pathway. <i>Medical Hypotheses</i> , 2003, 60, 634-639.	0.8	14
231	Effect of atorvastatin and pravastatin on serum C-reactive protein. <i>American Heart Journal</i> , 2003, 145, P1-P4.	1.2	34
232	Treating dyslipidemia with statins: The risk-benefit profile. <i>American Heart Journal</i> , 2003, 145, 387-396.	1.2	61
233	Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin. <i>Journal of Experimental Medicine</i> , 2003, 197, 725-733.	4.2	271
234	Coronary artery disease: New insights into the pathophysiology, prevalence and early detection of a monster menace. <i>Seminars in Ultrasound, CT and MRI</i> , 2003, 24, 114-122.	0.7	3
235	Inflammation, infection, and atherosclerosis. <i>Brain, Behavior, and Immunity</i> , 2003, 17, 238-244.	2.0	25
236	Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation</i> , 2003, 108, 2292-2297.	1.6	412
237	Statin effects beyond lipid lowering—are they clinically relevant?. <i>European Heart Journal</i> , 2003, 24, 225-248.	1.0	426
238	Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. <i>Expert Review of Cardiovascular Therapy</i> , 2003, 1, 495-505.	0.6	95
240	Statin Therapy in the Elderly. <i>Drugs and Aging</i> , 2003, 20, 263-275.	1.3	19
241	Pharmacotherapy for dyslipidaemia — current therapies and future agents. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 1901-1938.	0.9	154
242	Early vascular benefits of statin therapy. <i>Current Medical Research and Opinion</i> , 2003, 19, 540-556.	0.9	159
243	Major Risk Factors for Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 947.	3.8	97
244	Diagnostic Implications of C-Reactive Protein. <i>Archives of Surgery</i> , 2003, 138, 220.	2.3	77
245	Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1605-1613.	3.0	286
247	The Potential Influence of Inflammation and Insulin Resistance on the Pathogenesis and Treatment of Atherosclerosis-Related Complications in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2422-2429.	1.8	120

#	ARTICLE	IF	CITATIONS
248	Inflammation-Sensitive Plasma Proteins, Diabetes, and Mortality and Incidence of Myocardial Infarction and Stroke: A Population-Based Study. <i>Diabetes</i> , 2003, 52, 442-447.	0.3	138
249	Erythrocyte Sedimentation Rate, an Independent Predictor of Coronary Heart Disease in Men and Women: The Reykjavik Study. <i>American Journal of Epidemiology</i> , 2003, 158, 844-851.	1.6	103
250	Statin Therapy Interacts With Cytomegalovirus Seropositivity and High C-Reactive Protein in Reducing Mortality Among Patients With Angiographically Significant Coronary Disease. <i>Circulation</i> , 2003, 107, 258-263.	1.6	48
251	Prevention of Cardiovascular Ischemic Events. <i>Circulation</i> , 2003, 107, 2059-2065.	1.6	47
252	Review: Lipid lowering drugs, inflammation and cardiovascular disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2003, 3, 178-182.	0.6	2
253	Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 512-517.	1.1	114
254	C-Reactive Protein. <i>Circulation</i> , 2003, 108, e81-5.	1.6	327
255	Hormone Replacement Therapy and Inflammation. <i>Hypertension</i> , 2003, 42, 657-663.	1.3	65
256	Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. <i>Circulation</i> , 2003, 108, 161-165.	1.6	240
257	High Sensitivity C-Reactive Protein in Clinical Practice. <i>The American Heart Hospital Journal</i> , 2003, 1, 207-211.	0.2	25
258	Statins Promote Potent Systemic Antioxidant Effects Through Specific Inflammatory Pathways. <i>Circulation</i> , 2003, 108, 426-431.	1.6	380
259	Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor- κ B, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 4496-4501.	1.8	198
260	First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes. <i>Diabetes Care</i> , 2003, 26, 819-824.	4.3	215
261	Are Statins Indicated for the Primary Prevention of Coronary Heart Disease in Octogenarians? Protagonist Viewpoint. <i>The American Journal of Geriatric Cardiology</i> , 2003, 12, 351-354.	0.7	1
262	Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment. <i>Clinical Chemistry</i> , 2003, 49, 1258-1271.	1.5	198
263	Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart Disease. <i>Clinical Chemistry</i> , 2003, 49, 1347-1352.	1.5	51
264	C-Reactive Protein and Ischemia in Users and Nonusers of β -Blockers and Statins. <i>Circulation</i> , 2003, 107, 245-250.	1.6	66
265	High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study. <i>Circulation</i> , 2003, 108, 1560-1566.	1.6	383

#	ARTICLE	IF	CITATIONS
266	C-reactive protein and cardiovascular disease: new insights from an old molecule. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 793-807.	0.2	199
267	C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1039-1041.	0.4	12
268	Endothelium-Dependent Effects of Statins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 729-736.	1.1	372
269	The Statins: Multifunctional Antithrombotic and Antineoplastic Drugs. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 259-274.	1.5	11
270	Pathophysiology of Atherosclerotic Plaque Development and Rupture: An Overview. <i>Seminars in Vascular Medicine</i> , 2003, 03, 347-354.	2.1	20
271	Novel Biomedical Risk Markers for Cardiovascular Disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 41-55.	3.1	2
272	Therapie der Arteriosklerose. <i>Deutsche Medizinische Wochenschrift</i> , 2003, 128, 41-47.	1.0	5
273	C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary Syndromes. <i>Seminars in Vascular Medicine</i> , 2003, 03, 375-384.	2.1	32
274	Platelet Activation, Inflammatory Mediators and Hypercholesterolemia. <i>Current Vascular Pharmacology</i> , 2003, 1, 157-169.	0.8	64
275	Advances in antiplatelet therapy. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 349-363.	1.0	22
276	Risk assessment in cardiovascular disease: from traditional risk factors to genomics. <i>European Heart Journal Supplements</i> , 2003, 5, F48-F55.	0.0	1
277	3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors Protect Against Oxidized Low-Density Lipoprotein-Induced Endothelial Dysfunction. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2003, 10, 17-21.	1.7	35
278	C-Reactive Protein: A Novel Marker of Cardiovascular Risk. <i>Cardiology in Review</i> , 2003, 11, 169-179.	0.6	50
279	Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease. <i>Heart Disease (Hagerstown, Md)</i> , 2003, 5, 18-33.	1.3	7
280	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2003, 14, 111-113.	1.2	0
281	Evolution of Cholesterol Management Therapies: Exploiting Potential for Further Improvement. <i>American Journal of Therapeutics</i> , 2003, 10, 275-281.	0.5	9
282	Statins, Inflammation, and Sepsis*. <i>Chest</i> , 2003, 124, 740-743.	0.4	130
283	A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. <i>Annals of Medicine</i> , 2003, 35, 398-403.	1.5	73

#	ARTICLE	IF	CITATIONS
284	Cardiovascular Disease in Type 2 Diabetes Mellitus. Archives of Internal Medicine, 2003, 163, 33.	4.3	132
285	Benefits of Aggressive Drug Therapy. Journal of Cardiovascular Nursing, 2003, 18, 79-84.	0.6	1
286	C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 32, 210-214.	0.9	81
287	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, 41-55.	1.5	10
288	Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events. Current Opinion in Cardiology, 2003, 18, 471-478.	0.8	82
289	Inflammatory biomarkers of the patient with myocardial insufficiency. Current Opinion in Critical Care, 2003, 9, 369-374.	1.6	9
290	Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy. JAMA - Journal of the American Medical Association, 2003, 289, 1675.	3.8	401
291	hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels. Heart Disease (Hagerstown, Md), 2003, 5, 2-7.	1.3	49
292	C-reactive protein and interleukin-6 in vascular disease. Journal of Hypertension, 2003, 21, 1787-1803.	0.3	152
294	Interrelationship of Free Oxygen Radicals and Endothelial Dysfunction-Modulation by Statins. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 23-33.	1.7	58
295	Inflammation and Atherosclerosis in End-Stage Renal Disease. Blood Purification, 2003, 21, 29-36.	0.9	76
296	The Value of C-Reactive Protein in Cardiovascular Risk Prediction. Archives of Internal Medicine, 2003, 163, 1323.	4.3	113
297	Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease. Annals of Internal Medicine, 2003, 139, 670.	2.0	167
298	Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits. Clinical Science, 2003, 105, 655-662.	1.8	26
299	Statins and their role in vascular protection. Clinical Science, 2003, 105, 251-266.	1.8	100
300	Atherosclerosis and HIV Infection: Diagnosis and Treatment. , 2003, 40, 140-150.		1
301	Metabolic Effects of Infection on Protein and Energy Status. Journal of Nutrition, 2003, 133, 322S-327S.	1.3	70
302	C-reactive protein as a novel biomarker. Postgraduate Medicine, 2003, 114, 39-44.	0.9	21

#	ARTICLE	IF	CITATIONS
303	Evidence of prolonged disturbances in the haemostatic, hemorheologic and inflammatory profiles in transmural myocardial infarction survivors. <i>Thrombosis and Haemostasis</i> , 2003, 89, 892-903.	1.8	17
304	Identifying Women at Risk for Coronary Artery Disease. <i>AAOHN Journal</i> , 2003, 51, 15-22.	0.5	3
305	The place of ezetimibe in clinical practice. <i>British Journal of Hospital Medicine</i> , 2003, 64, 473-478.	0.3	3
306	C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003, 285, R1250-R1252.	0.9	38
308	The Role of Chronic Inflammation in Cardiovascular Mortality of Uremic Patients. <i>International Journal of Artificial Organs</i> , 2003, 26, 12-18.	0.7	0
309	Statins and Reduction of Stroke: Cholesterol-Lowering versus Pleiotropic Effects. , 2004, , 113-141.		0
310	The Pleiotropic Effects of Statins: Relevance to Their Salutary Effects. , 2004, , 163-187.		4
311	Effects of Statins on C-Reactive Protein: Are All Statins Similar?. , 2004, , 189-201.		0
312	Statins, Inflammation, and C-Reactive Protein. , 2004, , 219-232.		0
313	Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. <i>Journal of Applied Physiology</i> , 2004, 96, 143-148.	1.2	31
314	C-Reactive Protein and Peripheral Artery Disease among Japanese Elderly: the Tsurugaya Project. <i>Hypertension Research</i> , 2004, 27, 955-961.	1.5	40
315	Global Analysis of RNA Expression Profile in Human Vascular Cells Treated with Statins. <i>Journal of Atherosclerosis and Thrombosis</i> , 2004, 11, 62-72.	0.9	64
316	HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1676-1681.	0.5	45
317	Endothelial Secretory Function and Atherothrombosis. , 0, , 267-276.		5
319	C-Reactive Protein and Atherosclerosis of the Thoracic Aorta. <i>Archives of Internal Medicine</i> , 2004, 164, 1781.	4.3	24
320	Lipid-lowering therapy. <i>Postgraduate Medicine</i> , 2004, 115, 29-36.	0.9	2
321	New nonlipid effects of statins and their clinical relevance in cardiovascular disease. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1065-1077.	1.8	60
322	Plasma C-Reactive Protein and Homocysteine Concentrations Are Related to Frequent Fruit and Vegetable Intake in Hispanic and Non-Hispanic White Elders. <i>Journal of Nutrition</i> , 2004, 134, 913-918.	1.3	131

#	ARTICLE	IF	CITATIONS
323	Do statins play a role in the early management of the acute coronary syndrome?. European Heart Journal Supplements, 2004, 6, A32-A36.	0.0	5
324	Identifying patients at risk of coronary vascular disease: the potential role of inflammatory markers. European Heart Journal Supplements, 2004, 6, C21-C27.	0.0	7
325	Depression and C-Reactive Protein in US Adults. Archives of Internal Medicine, 2004, 164, 1010.	4.3	461
326	Stroke prevention with lipid-lowering therapy. Expert Review of Neurotherapeutics, 2004, 4, 233-239.	1.4	3
327	The Effects of Atorvastatin on Endothelial Function in Diabetic Patients and Subjects at Risk for Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 740-747.	1.8	122
328	Statins and the Myocardium. Seminars in Vascular Medicine, 2004, 4, 377-384.	2.1	20
329	Nontraditional Risk Factors for Cardiovascular Disease in Diabetes. Endocrine Reviews, 2004, 25, 153-175.	8.9	137
331	Associations of Postmenopausal Hormone Therapy with Markers of Hemostasis and Inflammation and Lipid Profiles in Diabetic and Nondiabetic American Indian Women: The Strong Heart Study. Journal of Women's Health, 2004, 13, 155-163.	1.5	16
332	Inflammation as a Cardiovascular Risk Factor. Circulation, 2004, 109, II2-10.	1.6	843
333	The Effect of Different Doses of Micronized 17 β -Estradiol on C-Reactive Protein, Interleukin-6, and Lipids in Older Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2004, 59, M827-M832.	1.7	52
335	Role of C-Reactive Protein in Cardiovascular Disease. Annals of Pharmacotherapy, 2004, 38, 110-118.	0.9	60
336	Inflammation in Atherosclerosis and Implications for Therapy. Circulation, 2004, 109, III-20-III-26.	1.6	267
337	Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?. Circulation, 2004, 109, 2818-2825.	1.6	578
338	Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 760-765.	2.5	329
339	Chapter 2 Primary Prevention of Stroke by Modification of Selected Risk Factors. Blue Books of Practical Neurology, 2004, 29, 5-54.	0.1	0
340	There Is No Evidence for an Increase in Acute Coronary Syndromes After Short-Term Abrupt Discontinuation of Statins in Stable Cardiac Patients. Circulation, 2004, 110, 2333-2335.	1.6	86
341	The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovascular Research, 2004, 62, 105-111.	1.8	248
342	Effect of Fenofibrate on Serum Inflammatory Markers in Patients With High Triglyceride Values. Journal of Cardiovascular Pharmacology and Therapeutics, 2004, 9, 27-33.	1.0	60

#	ARTICLE	IF	CITATIONS
343	Should Years of Schooling Be Used to Guide Treatment of Coronary Risk Factors?. <i>Annals of Family Medicine</i> , 2004, 2, 469-473.	0.9	31
344	Prevalence of High C-Reactive Protein in Persons with Serum Lipid Concentrations within Recommended Values. <i>Clinical Chemistry</i> , 2004, 50, 1618-1622.	1.5	25
345	Beyond the Laboratory: Clinical Implications for Statin Pleiotropy. <i>Circulation</i> , 2004, 109, II-42-II-48.	1.6	161
346	Statins for Stroke Prevention: Disappointment and Hope. <i>Circulation</i> , 2004, 109, III-44-III-49.	1.6	58
347	CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. <i>Circulation</i> , 2004, 110, e554-9.	1.6	58
348	Kidney Dysfunction, Inflammation, and Coronary Events: A Prospective Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1897-1903.	3.0	125
349	Nitric Oxide, Atherosclerosis and the Clinical Relevance of Endothelial Dysfunction. , 2004, , 55-70.		0
350	Risk Stratification and Prognostic Implication of Plasma Biomarkers in Nondiabetic Patients With Stable Coronary Artery Disease. <i>Chest</i> , 2004, 126, 1032-1039.	0.4	40
351	Early Withdrawal of Statin Therapy in Patients With Non-“ST-Segment Elevation Myocardial Infarction_{title>National Registry of Myocardial Infarction}. <i>Archives of Internal Medicine</i> , 2004, 164, 2162.	4.3	104
352	Improving outcomes through statin therapy ? a review of ongoing trials. <i>European Heart Journal Supplements</i> , 2004, 6, A28-A31.	0.0	8
353	Clinical Usefulness of Very High and Very Low Levels of C-Reactive Protein Across the Full Range of Framingham Risk Scores. <i>Circulation</i> , 2004, 109, 1955-1959.	1.6	446
354	Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. <i>European Heart Journal</i> , 2004, 25, 1754-1760.	1.0	66
355	The Dichotomous Role of Nitric Oxide in the Pathogenesis of Accelerated Atherosclerosis Associated with Systemic Lupus Erythematosus. <i>Current Molecular Medicine</i> , 2004, 4, 777-786.	0.6	8
356	Is there a need for novel cardiovascular risk factors?. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 761-765.	0.4	21
357	Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. <i>Upsala Journal of Medical Sciences</i> , 2004, 109, 71-122.	0.4	3
358	Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events. <i>Circulation</i> , 2004, 109, IV-6-IV-19.	1.6	313
359	Statins: can the new generation make an impression?. <i>Expert Opinion on Emerging Drugs</i> , 2004, 9, 269-279.	1.0	26
360	Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study. <i>Circulation</i> , 2004, 109, 837-842.	1.6	598

#	ARTICLE	IF	CITATIONS
361	Biomarkers of cardiac disease. Expert Review of Molecular Diagnostics, 2004, 4, 805-820.	1.5	24
362	Nuclear factor κ B: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovascular Research, 2004, 61, 671-682.	1.8	198
363	Statin Inhibition of Fc Receptor-Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2051-2056.	1.1	66
364	Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart Disease. Circulation, 2004, 110, 915-920.	1.6	121
365	Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. Current Medical Research and Opinion, 2004, 20, 55-62.	0.9	44
366	Highly sensitive determination of C-reactive protein on the Innotrac Aio! immunoanalyzer. Scandinavian Journal of Clinical and Laboratory Investigation, 2004, 64, 677-686.	0.6	12
367	Statins: potent vascular anti-inflammatory agents. International Journal of Clinical Practice, 2004, 58, 41-48.	0.8	24
368	Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.. Diabetes, Obesity and Metabolism, 2004, 6, 299-307.	2.2	5
369	Activation of the complement system: a crucial link between inflammation and atherosclerosis?. European Journal of Clinical Investigation, 2004, 34, 800-802.	1.7	23
370	Rationale, design and methods of the CASHMERE study+. Fundamental and Clinical Pharmacology, 2004, 18, 131-138.	1.0	19
371	Statins and autoimmune diseases. APLAR Journal of Rheumatology, 2004, 7, 278-284.	0.2	1
372	Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney International, 2004, 66, 338-347.	2.6	108
373	The Current and Future Role of Percutaneous Coronary Intervention in Patients with Coronary Artery Disease. Journal of Interventional Cardiology, 2004, 17, 283-294.	0.5	3
374	POOR NUTRITIONAL STATUS AND INFLAMMATION: C-Reactive Protein and End-Stage Renal Disease. Seminars in Dialysis, 2004, 17, 438-448.	0.7	62
375	Long-term effects of a high-protein, low-carbohydrate diet on weight control and cardiovascular risk markers in obese hyperinsulinemic subjects. International Journal of Obesity, 2004, 28, 661-670.	1.6	208
376	Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. American Journal of Transplantation, 2004, 4, 13-53.	2.6	320
377	Selenoproteins, Cholesterol-Lowering Drugs, and the Consequences Revisiting of the Mevalonate Pathway. Trends in Cardiovascular Medicine, 2004, 14, 273-281.	2.3	94
378	Approach to the patient with chest pain and nonobstructive coronary artery disease. Progress in Cardiovascular Diseases, 2004, 46, 453-464.	1.6	5

#	ARTICLE	IF	CITATIONS
379	Dialysis Outcomes and Practice Patterns Study (DOPPS) data on medications in hemodialysis patients. American Journal of Kidney Diseases, 2004, 44, 61-67.	2.1	32
380	High-sensitivity C-reactive protein. Current Problems in Cardiology, 2004, 29, 439-493.	1.1	30
381	Early effects of statins in patients with coronary artery disease and high C-reactive protein. American Journal of Cardiology, 2004, 94, 1107-1112.	0.7	25
382	Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction. American Journal of Cardiology, 2004, 94, 1113-1117.	0.7	7
383	Evidence for C-Reactive Protein's Role in (CRP) Vascular Disease: Atherothrombosis, Immuno-Regulation and CRP. Journal of Thrombosis and Thrombolysis, 2004, 17, 95-105.	1.0	58
384	Endothelial Dysfunction, Inflammation and Diabetes. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 189-197.	2.6	69
385	Lipid management with statins. Clinical Research in Cardiology, 2004, 93, 4-9.	1.2	11
387	Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. Journal of Infection, 2004, 49, 283-290.	1.7	46
388	Long-term effects of advice to consume a high-protein, low-fat diet, rather than a conventional weight-loss diet, in obese adults with Type 2 diabetes: one-year follow-up of a randomised trial. Diabetologia, 2004, 47, 1677-1686.	2.9	155
389	Diabetes and Inflammation. Herz, 2004, 29, 749-759.	0.4	25
391	Inflammation and atherosclerosis. Current Atherosclerosis Reports, 2004, 6, 131-139.	2.0	56
392	A new era in atherosclerosis drug discovery. Expert Review of Cardiovascular Therapy, 2004, 2, 633-636.	0.6	4
393	Accelerated atherosclerosis in inflammatory rheumatic diseases. Scandinavian Journal of Rheumatology, 2004, 33, 281-292.	0.6	48
394	Genetic Polymorphisms in Cytochrome P450 Enzymes. American Journal of Cardiovascular Drugs, 2004, 4, 247-255.	1.0	35
395	Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?. Circulation, 2004, 109, II-18-II-26.	1.6	417
396	Statins in Stroke Prevention and Carotid Atherosclerosis. Stroke, 2004, 35, 2902-2909.	1.0	686
397	Plasma C-Reactive Protein Concentrations in Active and Passive Smokers: Influence of Antioxidant Supplementation. Journal of the American College of Nutrition, 2004, 23, 141-147.	1.1	73
399	Secondary Prevention Strategies in Ischemic Stroke: Identification and Optimal Management of Modifiable Risk Factors. Mayo Clinic Proceedings, 2004, 79, 1330-1340.	1.4	34

#	ARTICLE	IF	CITATIONS
400	Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. <i>Journal of Vascular Surgery</i> , 2004, 39, 1178-1185.	0.6	168
404	Inflammation in Acute Coronary Syndromes: Mechanisms and Clinical Implications. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 433-446.	0.4	7
405	Effect of the Early Administration of Pravastatin on C-Reactive Protein and Interleukin-6 Levels in the Acute Phase of Myocardial Infarction With ST Segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2004, 57, 916-923.	0.4	0
406	A novel technique to assess flow-mediated vasodilation**Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1478-1480.	1.2	1
407	The Metabolic Syndrome and Inflammation. <i>Metabolic Syndrome and Related Disorders</i> , 2004, 2, 82-104.	0.5	178
408	Medical Lipid-Regulating Therapy. <i>Drugs</i> , 2004, 64, 1181-1196.	4.9	68
409	Investigating cardiovascular risk reduction â€“ the Rosuvastatin GALAXY Programmeâ„¢. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 1187-1200.	0.9	34
410	Lipaemia, Inflammation and Atherosclerosis. <i>Drugs</i> , 2004, 64, 19-41.	4.9	59
411	Statins in Hypertensive Patients. <i>Drugs</i> , 2004, 64, 61-67.	4.9	5
412	Pharmacoepidemiology and disability in older adults: can medications slow the age-related decline in physical function?. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 407-413.	0.9	11
413	C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease. <i>New England Journal of Medicine</i> , 2004, 350, 1387-1397.	13.9	2,608
414	Quality specifications and the assessment of the biochemical risk of atherosclerosis. <i>Clinica Chimica Acta</i> , 2004, 346, 55-64.	0.5	16
415	Evaluation of diagnostic relevance of mRNA levels in peripheral blood: predictive value for mortality in hemodialysis patients. <i>Cytokine</i> , 2004, 27, 166-172.	1.4	16
416	Coronary artery disease: new insights into the pathophysiology, prevalence, and early detection of a monster menace. <i>Seminars in Ultrasound, CT and MRI</i> , 2004, 25, 113-121.	0.7	8
417	In face of the increasing efficacy of lipid-lowering therapy, is there still a place for LDL-apheresis?. <i>Transfusion and Apheresis Science</i> , 2004, 30, 213-220.	0.5	4
418	Does aggressive statin therapy offer improved cholesterol-independent benefits compared to conventional statin treatment?. <i>International Journal of Cardiology</i> , 2004, 96, 131-139.	0.8	14
419	AMPK activation may suppress hepatic production of C-reactive protein by stimulating nitric oxide synthase. <i>Medical Hypotheses</i> , 2004, 63, 328-333.	0.8	20
420	Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction. <i>American Heart Journal</i> , 2004, 148, S3-S8.	1.2	14

#	ARTICLE	IF	CITATIONS
421	High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. <i>American Heart Journal</i> , 2004, 148, S19-S26.	1.2	235
422	Inflammation and atherosclerosis: role of C-Reactive protein in risk assessment. <i>American Journal of Medicine</i> , 2004, 116, 9-16.	0.6	492
423	C-reactive protein: From innocent bystander to pivotal mediator of atherosclerosis. <i>American Journal of Medicine</i> , 2004, 117, 499-507.	0.6	136
424	Statin-induced immunomodulatory effects on human T cells in vivo. <i>Atherosclerosis</i> , 2004, 175, 83-90.	0.4	101
425	Diet for preventing cardiovascular diseases. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2004, 14, 52-57.	1.1	23
426	Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1571-1575.	0.5	116
427	Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. <i>Kidney International</i> , 2004, 65, 1009-1016.	2.6	629
428	A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. <i>Atherosclerosis</i> , 2004, 174, 349-356.	0.4	75
429	Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2004, 177, 161-166.	0.4	170
430	Goals of Statin Therapy: Three Viewpoints. <i>Atherosclerosis Supplements</i> , 2004, 5, 107-114.	1.2	4
431	Mevastatin inhibits ovarian thecaâ€“interstitial cell proliferation and steroidogenesis. <i>Fertility and Sterility</i> , 2004, 82, 1193-1197.	0.5	82
432	Statins and rheumatoid arthritis. <i>Lancet, The</i> , 2004, 364, 1853.	6.3	3
433	Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. <i>American Journal of Clinical Nutrition</i> , 2004, 79, 544-551.	2.2	374
434	Treatment of Dyslipidemia in Chronic Kidney Disease. <i>International Journal of Artificial Organs</i> , 2004, 27, 821-827.	0.7	3
435	Statins and myocardial hypertrophy. <i>Coronary Artery Disease</i> , 2004, 15, 247-250.	0.3	20
436	New Clinical Markers Predictive of Cardiovascular Disease. <i>Cardiology in Review</i> , 2004, 12, 151-157.	0.6	14
437	Focusing on Inflammation in the Treatment of Atherosclerosis. <i>Cardiology in Review</i> , 2004, 12, 194-200.	0.6	15
438	Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. <i>Coronary Artery Disease</i> , 2004, 15, 235-242.	0.3	60

#	ARTICLE	IF	CITATIONS
439	Current and future concepts in stroke prevention. <i>Cmaj</i> , 2004, 170, 1123-1133.	0.9	32
440	C-reactive protein for the prediction of cardiovascular risk: Ready for prime-time?. <i>Cmaj</i> , 2004, 170, 1563-1565.	0.9	8
441	Inflammation and cardiovascular diseases: lessons that can be learned for the patient with cardiogenic shock in the intensive care unit. <i>Current Opinion in Critical Care</i> , 2004, 10, 347-353.	1.6	10
442	Is Dressler Syndrome Dead?. <i>Chest</i> , 2004, 126, 1680-1682.	0.4	47
443	Prevention of restenosis after stenting: the emerging role of inflammation. <i>Coronary Artery Disease</i> , 2004, 15, 307-311.	0.3	41
444	Markers of Myocardial Injury and Dysfunction. <i>AACN Advanced Critical Care</i> , 2004, 15, 547-557.	1.9	9
445	Treatment and Prevention of Dyslipidemia with Rosuvastatin (Crestor). <i>Nurse Practitioner</i> , 2004, 29, 11-15.	0.2	2
446	The role of fat-soluble nutrients and antioxidants in preventing heart disease. , 2004, , 56-76.		1
447	Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease. <i>Clinical Science</i> , 2004, 106, 511-517.	1.8	19
448	Association between Serum C-reactive Protein Levels and Microalbuminuria: A Population-Based Cross-Sectional Study in Northern Iwate, Japan. <i>Internal Medicine</i> , 2004, 43, 919-925.	0.3	79
449	Statin Therapy for Cardiac Hypertrophy and Heart Failure. <i>Journal of Investigative Medicine</i> , 2004, 52, 248-253.	0.7	45
450	High-sensitivity C-reactive protein Clinical importance. <i>Current Problems in Cardiology</i> , 2004, 29, 439-493.	1.1	132
451	Role of Inflammation and Infection in Vascular Disease. <i>Acta Chirurgica Belgica</i> , 2005, 105, 567-579.	0.2	48
452	The pleiotropic effects of statins. <i>Current Opinion in Cardiology</i> , 2005, 20, 541-546.	0.8	138
453	Clinical implications for statin pleiotropy. <i>Current Opinion in Lipidology</i> , 2005, 16, 624-629.	1.2	123
454	Radionuclide-Based Insights into the Pathophysiology of Ischemic Heart Disease: Beyond Diagnosis. <i>Journal of Investigative Medicine</i> , 2005, 53, 176-191.	0.7	7
455	Elevated Preprocedural High-Sensitivity C-Reactive Protein Levels are Associated With Neointimal Hyperplasia and Restenosis Development After Successful Coronary Artery Stenting. <i>Circulation Journal</i> , 2005, 69, 1477-1483.	0.7	34
456	Matrix Metalloproteinases and Diabetic Vascular Complications. <i>Angiology</i> , 2005, 56, 173-189.	0.8	122

#	ARTICLE	IF	CITATIONS
457	The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2005, 28, 243-246.	0.7	12
458	High-sensitivity C-reactive protein as a risk assessment tool for cardiovascular disease. <i>Clinical Cardiology</i> , 2005, 28, 408-412.	0.7	78
459	Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis. <i>Hemodialysis International</i> , 2005, 9, 7-22.	0.4	16
460	Biomarkers of inflammation and progression of chronic kidney disease. <i>Kidney International</i> , 2005, 68, 237-245.	2.6	309
461	Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 977-987.	21.5	760
462	Direct comparison of dietary portfolio vs statin on C-reactive protein. <i>European Journal of Clinical Nutrition</i> , 2005, 59, 851-860.	1.3	64
463	Statins and Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1093-1110.	2.4	170
464	High-sensitivity serum C-reactive protein levels in subjects with or without myocardial infarction or periodontitis. <i>Journal of Clinical Periodontology</i> , 2005, 32, 219-224.	2.3	43
465	Pharmacogenomics and cardiovascular drugs: Need for integrated biological system with phenotypes and proteomic markers. <i>European Journal of Pharmacology</i> , 2005, 527, 1-22.	1.7	32
466	Relation of C-Reactive Protein and One-Year Survival After Acute Myocardial Infarction With Versus Without Statin Therapy. <i>American Journal of Cardiology</i> , 2005, 96, 617-621.	0.7	21
467	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2005, 96, 24-33.	0.7	243
468	Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. <i>Free Radical Biology and Medicine</i> , 2005, 39, 444-452.	1.3	62
469	Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 39-47.	2.1	153
470	Inflammatory markers in depressed post-myocardial infarction patients. <i>Journal of Psychiatric Research</i> , 2005, 39, 137-144.	1.5	54
471	Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors on High-Sensitivity C-Reactive Protein Levels. <i>Pharmacotherapy</i> , 2005, 25, 1365-1377.	1.2	9
472	Effects of Atorvastatin on Low-Density Lipoprotein Cholesterol Phenotype and C-Reactive Protein Levels in Patients Undergoing Long-Term Dialysis. <i>Pharmacotherapy</i> , 2005, 25, 335-344.	1.2	21
473	Antiarrhythmic Mechanisms of n-3 PUFA and the Results of the GISSI-Prevenzione Trial. <i>Journal of Membrane Biology</i> , 2005, 206, 117-128.	1.0	34
474	Interaction between simvastatin and metoprolol with respect to cardiac β_2 -adrenoceptor density, catecholamine levels and perioperative catecholamine requirements in cardiac surgery patients. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2005, 372, 115-124.	1.4	19

#	ARTICLE	IF	CITATIONS
475	Heart failure and statinsâ€”Why do we need a clinical trial?. <i>Clinical Research in Cardiology</i> , 2005, 94, 223-230.	1.2	23
478	Platelets and atherothrombosis: An essential role for inflammation in vascular disease â€” A review. <i>International Journal of Angiology</i> , 2005, 14, 211-217.	0.2	5
479	Role of anti-infective strategies in the prevention of stroke. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 187-195.	0.4	1
480	Novel serologic markers of cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2005, 7, 148-154.	2.0	12
481	Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk. <i>Current Atherosclerosis Reports</i> , 2005, 7, 22-28.	2.0	7
482	Pleiotropic effects of statins: Moving beyond cholesterol control. <i>Current Atherosclerosis Reports</i> , 2005, 7, 34-39.	2.0	19
483	Using biomarkers to assess risk and consider treatment strategies in non-ST-segment elevation acute coronary syndromes. <i>Current Cardiology Reports</i> , 2005, 7, 263-269.	1.3	2
484	Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk?. <i>Current Hypertension Reports</i> , 2005, 7, 379-384.	1.5	24
485	Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696]. <i>Current Controlled Trials in Cardiovascular Medicine</i> , 2005, 6, 4.	1.5	17
486	Modulating T cell signaling cascades by HMG-CoA reductase inhibitors. <i>Signal Transduction</i> , 2005, 5, 231-244.	0.7	3
489	The Source of Inflammatory Response and Platelet Activation in Patients with Acute Myocardial Infarction. <i>Korean Circulation Journal</i> , 2005, 35, 155.	0.7	1
490	Prevention of cardiovascular disease in type-2 diabetes: How to improve the clinical efficacy of aspirin. <i>Thrombosis and Haemostasis</i> , 2005, 93, 8-16.	1.8	57
492	Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. <i>European Journal of Heart Failure</i> , 2005, 7, 1126-1132.	2.9	96
493	White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin. <i>Circulation</i> , 2005, 111, 1756-1762.	1.6	59
494	Besteht Bedarf an neuen kardiovaskulÃ¤ren Risikofaktoren? Is there a need for new cardiovascular risk factors?. <i>Das Medizinische Laboratorium</i> , 2005, 29, 146-151.	0.0	0
495	Type 2 Diabetes As An Inflammatory Cardiovascular Disorder. <i>Current Molecular Medicine</i> , 2005, 5, 309-322.	0.6	78
496	Statin Use and Fracture Risk. <i>Archives of Internal Medicine</i> , 2005, 165, 2007.	4.3	71
497	HMG-CoA Reductase Inhibitors Inhibit Endothelial Exocytosis and Decrease Myocardial Infarct Size. <i>Circulation Research</i> , 2005, 96, 1185-1192.	2.0	75

#	ARTICLE	IF	CITATIONS
499	C-Reactive Protein and Cerebral Small-Vessel Disease. <i>Circulation</i> , 2005, 112, 900-905.	1.6	296
500	Statins and autoimmune diseases. <i>Lupus</i> , 2005, 14, 765-768.	0.8	21
501	Inflammation in Atherosclerosis: New Opportunities for Drug Discovery. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 33-40.	1.1	5
502	A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. <i>European Heart Journal</i> , 2005, 26, 2664-2672.	1.0	101
503	Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. <i>Cmaj</i> , 2005, 172, 1199-1209.	0.9	195
504	Global Risk Stratification to Improve Cardiovascular Prevention: Integration of Traditional Risk Factors, Emerging Risk Factors, and New, Noninvasive Cardiovascular Imaging. <i>The American Heart Hospital Journal</i> , 2005, 3, 265-268.	0.2	0
505	Ambient Particulate Matter, C-Reactive Protein, and Coronary Artery Disease. <i>Inhalation Toxicology</i> , 2005, 17, 409-413.	0.8	31
506	Development of an In Vitro Screening Assay to Test the Antiinflammatory Properties of Dietary Supplements and Pharmacologic Agents. <i>Clinical Chemistry</i> , 2005, 51, 2252-2256.	1.5	65
507	Inflammatory, atherothrombotic aspects of type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2005, 21, S5-S12.	0.9	23
508	Inflammatory markers and cardiovascular health in older adults. <i>Cardiovascular Research</i> , 2005, 66, 265-275.	1.8	182
509	Pathogenesis of Atherosclerotic Vascular Disease. , 2005, , 99-181.		0
510	Lower Extremity Arterial Disease. , 2005, , .		2
511	Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke. <i>Stroke</i> , 2005, 36, 1316-1329.	1.0	256
512	Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?. <i>Heart</i> , 2005, 91, 1-2.	1.2	163
513	Inflammation in coronary artery disease: potential role for immunomodulatory therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 1111-1124.	0.6	12
514	Cholesterol-independent Effects of Statins in Inflammation, Immunomodulation and Atherosclerosis. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2005, 5, 127-134.	2.0	40
515	Statin Monotherapy Attenuates Renal Injury in a Salt-Sensitive Hypertension Model of Renal Disease. <i>Nephron Physiology</i> , 2005, 101, p82-p91.	1.5	21
516	Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease. <i>Circulation</i> , 2005, 112, 171-178.	1.6	188

#	ARTICLE	IF	CITATIONS
517	The Functional Role of C-Reactive Protein in Aortic Wall Calcification. <i>Cardiology</i> , 2005, 104, 57-64.	0.6	16
518	C-Reactive Protein Predicts Death in Patients with Non-Ischemic Cardiomyopathy. <i>Cardiology</i> , 2005, 104, 196-201.	0.6	13
519	Elevated Levels of High-Sensitivity C-Reactive Protein and Serum Amyloid-A Late After Kawasaki Disease. <i>Circulation</i> , 2005, 111, 38-43.	1.6	133
520	Inflammatory Biomarkers for Prediction of Outcomes After Unprotected Left Main Coronary Intervention. <i>Circulation</i> , 2005, 112, 2226-2227.	1.6	5
521	Biochemical risk markers: a novel area for better prediction of renal risk?. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 497-508.	0.4	19
522	The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2005, 98, 599-614.	0.2	44
523	Evolution of C-Reactive Protein as a Cardiac Risk Factor. <i>Laboratory Medicine</i> , 2005, 36, 234-238.	0.8	4
524	The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors. <i>Country Review Ukraine</i> , 2005, 7, C5-C11.	0.8	25
525	El paradigma inmune Th1-Th2: un vínculo entre obesidad, aterosclerosis y diabetes mellitus. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2005, 17, 232-248.	0.4	0
526	Marcadores biol3gicos de inflamaci3n y control del tratamiento hipolipemiante. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2005, 17, 25-30.	0.4	0
528	Non-HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in Women. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 326.	3.8	639
529	Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. <i>Atherosclerosis</i> , 2005, 179, 361-367.	0.4	71
530	What causes acute coronary syndromes? Applying Koch's postulates. <i>Atherosclerosis</i> , 2005, 179, 1-15.	0.4	29
531	Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population. <i>Atherosclerosis</i> , 2005, 180, 189-195.	0.4	104
532	The inflammation: Lipoprotein cycle. <i>Atherosclerosis Supplements</i> , 2005, 6, 15-20.	1.2	44
533	Markers of inflammation and their clinical significance. <i>Atherosclerosis Supplements</i> , 2005, 6, 21-29.	1.2	125
534	Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2005, 4, 371-380.	4.9	330
535	Changes in Flow-Mediated Dilatation, Cytokines and Carotid Arterial Stenosis During Aggressive Atorvastatin Treatment in Normocholesterolemic Patients. <i>Journal of the Chinese Medical Association</i> , 2005, 68, 53-58.	0.6	9

#	ARTICLE	IF	CITATIONS
536	Traditional and Emerging Risk Factors for Cardiovascular Disease. Primary Care - Clinics in Office Practice, 2005, 32, 963-976.	0.7	23
538	Management of Cardiovascular Disease in the Renal Transplant Recipient. Cardiology Clinics, 2005, 23, 331-342.	0.9	11
539	Drug Insight: statins and stroke. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 576-584.	3.3	25
540	Statins and the Response to Myocardial Injury. American Journal of Cardiovascular Drugs, 2005, 5, 163-170.	1.0	13
541	Pathophysiology of Coronary Artery Disease. Circulation, 2005, 111, 3481-3488.	1.6	1,467
542	C-reactive protein comes of age. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 29-36.	3.3	187
543	The Role of Statins in Preventing Stroke. Preventive Cardiology, 2005, 8, 98-101.	1.1	7
544	CRP after 2004. Molecular Immunology, 2005, 42, 927-930.	1.0	88
545	Lifestyle-only intervention attenuates the inflammatory state associated with obesity: A randomized controlled study in adolescents. Journal of Pediatrics, 2005, 146, 342-348.	0.9	180
546	Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. International Journal of Cardiology, 2005, 98, 199-206.	0.8	70
547	Secondary hyperparathyroidism promotes the acute phase response – a rationale for supplemental Vitamin D in prevention of vascular events in the elderly. Medical Hypotheses, 2005, 64, 1022-1026.	0.8	52
548	Role of hs-CRP measurements in the current cardiovascular risk assessment. Clinica Chimica Acta, 2005, 355, 215-218.	0.5	8
549	Immune-regulation of the apolipoprotein A-I/C-III/A-IV gene cluster in experimental inflammation. Cytokine, 2005, 31, 52-63.	1.4	74
550	Prognostic value of inflammatory markers alone and in combination with blood lipids in patients with stable coronary artery disease. European Journal of Internal Medicine, 2005, 16, 47-52.	1.0	17
551	Erythrocyte adhesiveness/aggregation: A novel biomarker for the detection of low-grade internal inflammation in individuals with atherothrombotic risk factors and proven vascular disease. American Heart Journal, 2005, 149, 260-267.	1.2	50
552	Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. American Heart Journal, 2005, 149, 473.e1-473.e10.	1.2	127
554	Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal, 2005, 149, 820-825.	1.2	225
555	Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. American Heart Journal, 2005, 150, 243-250.	1.2	44

#	ARTICLE	IF	CITATIONS
556	The biology, utilization, and attenuation of C-reactive protein in cardiovascular disease: Part II. American Heart Journal, 2005, 149, 977-983.	1.2	22
559	Dyslipidemias. , 2005, , 145-172.		0
560	C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine, 2005, 352, 20-28.	13.9	2,103
561	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed), 2005, 58, 934-940.	0.4	4
563	C-Reactive Protein and Electrocardiographic ST-Segment Depression Additively Predict Mortality. Journal of the American College of Cardiology, 2005, 45, 1787-1793.	1.2	17
564	Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l. Journal of the American College of Cardiology, 2005, 45, 1644-1648.	1.2	219
565	Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E. Journal of the American College of Cardiology, 2005, 46, 166-172.	1.2	380
566	Atherothrombosis and High-Risk Plaque. Journal of the American College of Cardiology, 2005, 46, 937-954.	1.2	666
567	Race and Gender Differences in C-Reactive Protein Levels. Journal of the American College of Cardiology, 2005, 46, 464-469.	1.2	618
568	Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology, 2005, 46, 1219-1224.	1.2	48
569	Prospects for Personalized Cardiovascular Medicine. Journal of the American College of Cardiology, 2005, 46, 1615-1627.	1.2	65
570	Risk Factors for Atherosclerotic Vascular Disease. Handbook of Experimental Pharmacology, 2005, , 71-105.	0.9	21
571	PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology, 2005, 45, 89-118.	4.2	1,574
573	Cardiovascular Biomarkers. , 2006, , .		5
574	Cachexia: Therapeutic Immunomodulation Beyond Cytokine Antagonism. , 2006, , 741-753.		1
577	Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 738-744.	3.1	24
578	Present and Future Biochemical Markers for Detection of Acute Coronary Syndrome. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 427-495.	2.7	14
579	Statins: panacea for sepsis?. Lancet Infectious Diseases, The, 2006, 6, 242-248.	4.6	114

#	ARTICLE	IF	CITATIONS
580	Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. <i>Diabetes and Metabolism</i> , 2006, 32, 229-235.	1.4	24
581	PROVE-IT proves that lower is better: A contrary view. <i>Canadian Journal of Cardiology</i> , 2006, 22, 95B-96B.	0.8	0
582	Utilidad de los marcadores de inflamación en el diagnóstico del riesgo cardiovascular. <i>Clínica e Investigación En Arteriosclerosis</i> , 2006, 18, 56-71.	0.4	0
583	Controversies in stable coronary artery disease. <i>Lancet, The</i> , 2006, 367, 69-78.	6.3	56
584	Statin use and the risk of Alzheimer's disease: The MIRAGE Study. , 2006, 2, 96-103.		48
585	A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. <i>Atherosclerosis Supplements</i> , 2006, 7, 21-29.	1.2	6
586	Statins: Potential new indications in inflammatory conditions. <i>Atherosclerosis Supplements</i> , 2006, 7, 31-35.	1.2	107
587	Role of adhesion molecules in the induction of restenosis after angioplasty in the lower limb. <i>Journal of Vascular Surgery</i> , 2006, 43, 969-977.	0.6	14
588	Common Questions in Managing Hyperlipidemia. <i>Primary Care - Clinics in Office Practice</i> , 2006, 33, 903-921.	0.7	0
589	Inflammation, Atherosclerosis, and Cardiovascular Disease Risk: PAPP-A, Lp-PLA2, and Cystatin C. New Insights or Redundant Information?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2006, 59, 247-258.	0.4	11
591	Enfermedades cardiovasculares en la mujer: ¿por qué ahora?. <i>Revista Espanola De Cardiologia</i> , 2006, 59, 259-263.	0.6	29
593	High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus. <i>Diabetes Technology and Therapeutics</i> , 2006, 8, 28-36.	2.4	167
594	Physical Activity and High-Sensitivity C-Reactive Protein. <i>Sports Medicine</i> , 2006, 36, 443-458.	3.1	194
595	C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. <i>Journal of the American College of Cardiology</i> , 2006, 47, C19-C31.	1.2	295
596	Biomarkers in Acute Cardiac Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1-11.	1.2	1,289
597	Simvastatin Attenuates Plaque Inflammation. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1825-1831.	1.2	636
598	Inflammation and Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2006, 48, A33-A46.	1.2	157
599	Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2006, 55, 67-71.	1.5	14

#	ARTICLE	IF	CITATIONS
600	Do statins have a role in preventing or treating sepsis?. <i>Critical Care</i> , 2006, 10, 113.	2.5	38
601	High-Sensitivity C-Reactive Protein and Coronary Heart Disease Mortality in Patients With Type 2 Diabetes: A 7-year follow-up study. <i>Diabetes Care</i> , 2006, 29, 329-333.	4.3	153
602	Rapid Electrochemiluminoimmunoassay of Human C-Reactive Protein at Planar Disposable Oxide-Coated Silicon Electrodes. <i>Analytical Chemistry</i> , 2006, 78, 82-88.	3.2	44
603	The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2006, 368, 183-187.	0.5	15
604	Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials. <i>Clinical Therapeutics</i> , 2006, 28, 849-859.	1.1	18
605	Effects of atorvastatin 10 mg/d on insulin resistance: A 12-week, open-label study in hyperlipidemic patients. <i>Current Therapeutic Research</i> , 2006, 67, 44-54.	0.5	2
606	Pro-inflammatory cytokines in acute coronary syndromes: From bench to bedside. <i>Cytokine and Growth Factor Reviews</i> , 2006, 17, 225-233.	3.2	123
607	The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level. <i>International Journal of Cardiology</i> , 2006, 109, 48-52.	0.8	38
608	Statin use and survival in patients with chronic heart failure " results from two observational studies with 5200 patients. <i>International Journal of Cardiology</i> , 2006, 112, 234-242.	0.8	90
609	Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). <i>Acta Cardiologica</i> , 2006, 61, 327-331.	0.3	28
610	Importância da proteína C-reativa no diagnóstico e no prognóstico intra-hospitalar em pacientes com dor torácica na sala de emergência. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, 275-80.	0.3	10
611	New Frontiers for Cardiac Risk Assessment: C-Reactive Protein. <i>The Consultant Pharmacist</i> , 2006, 21, 188-206.	0.4	1
613	Obesity as an inflammatory condition. <i>Health SA Gesondheid</i> , 2006, 11, .	0.3	1
614	Effect of Cardiac Rehabilitation and Statin Treatment on Anti-HSP Antibody Titers in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention. <i>International Heart Journal</i> , 2006, 47, 671-682.	0.5	24
615	Inflammation, Cardiovascular Disease and the Metabolic Syndrome. , 2006, , 207-238.		0
616	Future approaches to reducing low-density lipoprotein cholesterol. <i>Future Lipidology</i> , 2006, 1, 463-476.	0.5	1
617	The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women. <i>Annals of Internal Medicine</i> , 2006, 145, 21.	2.0	445
618	Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2006, 145, 35.	2.0	231

#	ARTICLE	IF	CITATIONS
619	Potential role of statins and PPARs in rheumatoid arthritis. <i>Future Rheumatology</i> , 2006, 1, 259-274.	0.2	3
620	Inflammation and cardiovascular disease mechanisms. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 456S-460S.	2.2	891
621	Total Serum Cholesterol and Recovery From Disability Among Hospitalized Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 736-742.	1.7	15
622	Protection of Endothelial Function: Targets for Nutritional and Pharmacological Interventions. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, S136-S150.	0.8	58
623	Atherosclerosis, inflammation, leukocyte function and the effect of statins. <i>Journal of Hypertension</i> , 2006, 24, 2349-2351.	0.3	13
624	Arteries, inflammation and insulin resistance. <i>Journal of Hypertension</i> , 2006, 24, S18-S20.	0.3	11
625	Simvastatin treatment modifies polymorphonuclear leukocyte function in high-risk individuals: a longitudinal study. <i>Journal of Hypertension</i> , 2006, 24, 2423-2430.	0.3	31
626	C-reactive protein contributes to the hypercoagulable state in coronary artery disease. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 98-106.	1.9	24
627	UNRESOLVED ISSUES IN DIALYSIS: Inflammatory Biomarkers and Cardiovascular Risk: Association or Cause and Effect?. <i>Seminars in Dialysis</i> , 2006, 19, 129-135.	0.7	31
628	Statins and bone metabolism. <i>Oral Diseases</i> , 2006, 12, 85-101.	1.5	92
629	Atorvastatin interferes with activation of human CD4+T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis. <i>Clinical and Experimental Immunology</i> , 2006, 146, 524-532.	1.1	31
630	Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. <i>European Journal of Clinical Investigation</i> , 2006, 36, 76-84.	1.7	21
631	Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 262-274.	1.1	70
632	Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. <i>European Journal of Clinical Nutrition</i> , 2006, 60, 802-809.	1.3	127
633	C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients. <i>Journal of Human Hypertension</i> , 2006, 20, 587-592.	1.0	3
634	Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cyto-reductive potential?. <i>Leukemia Research</i> , 2006, 30, 1217-1225.	0.4	34
635	Ezetimibe: Rationale and role in the management of hypercholesterolemia. <i>Clinical Cardiology</i> , 2006, 29, 52-55.	0.7	8
636	Comparison of the National Emergency Department Overcrowding Scale and the Emergency Department Work Index for Quantifying Emergency Department Crowding. <i>Academic Emergency Medicine</i> , 2006, 13, 513-518.	0.8	85

#	ARTICLE	IF	CITATIONS
637	Fas Ligand mRNA Levels of Circulating Leukocytes Reflect Endothelial Dysfunction in Hyperlipidemic but Not in Non-Hyperlipidemic Patients. <i>Hypertension Research</i> , 2006, 29, 217-225.	1.5	5
638	Effects of Withdrawal of Xuezhikang, an Extract of Cholestin, on Lipid Profile and C-reactive Protein: A Short-Term Time Course Study in Patients with Coronary Artery Disease. <i>Cardiovascular Drugs and Therapy</i> , 2006, 20, 185-191.	1.3	13
639	Nitric oxide and superoxide in rat mesangial cells: modulation by C-reactive protein. <i>Pediatric Nephrology</i> , 2006, 21, 619-626.	0.9	11
640	Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 42-52.	0.5	29
641	Statins and the primary prevention of cardiovascular events. <i>Current Atherosclerosis Reports</i> , 2006, 8, 390-396.	2.0	22
643	Other than potency, are all statins the same?. <i>Current Atherosclerosis Reports</i> , 2006, 8, 26-31.	2.0	1
644	TGF- β 1-induced thrombospondin-1 expression through the p38 MAPK pathway is abolished by fluvastatin in human coronary artery smooth muscle cells. <i>Vascular Pharmacology</i> , 2006, 44, 469-475.	1.0	29
646	Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)â€”Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?. <i>American Journal of Cardiology</i> , 2006, 97, 33-41.	0.7	182
647	Coronary Artery Disease Prognosis and C-Reactive Protein Levels Improve in Proportion to Percent Lowering of Low-Density Lipoprotein. <i>American Journal of Cardiology</i> , 2006, 98, 135-139.	0.7	13
648	Effects of Colesevelam Hydrochloride (WelChol) on Biomarkers of Inflammation in Patients With Mild Hypercholesterolemia. <i>American Journal of Cardiology</i> , 2006, 98, 641-643.	0.7	42
649	Time Course of C-Reactive Protein Reduction With Simvastatin Therapy in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2006, 98, 1656-1659.	0.7	15
650	Inflammatory Biomarkers in Stable Atherosclerosis. <i>American Journal of Cardiology</i> , 2006, 98, S2-S8.	0.7	63
651	Pathophysiology, Diagnosis, and Management of Dyslipidemia. <i>Current Problems in Cardiology</i> , 2006, 31, 445-486.	1.1	29
654	Cardiovascular Biomarkers in CKD: Pathophysiology and Implications for Clinical Management of Cardiac Disease. <i>American Journal of Kidney Diseases</i> , 2006, 48, 341-360.	2.1	76
655	C-Reactive Protein and the Metabolic Syndrome: Useful Addition to the Cardiovascular Risk Profile?. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 66-69.	1.7	11
656	The metabolic syndrome. <i>Journal of Diabetes and Its Complications</i> , 2006, 20, 121-132.	1.2	79
657	Management of stable angina and unstable angina/non-ST-elevation myocardial infarction. <i>Medicine</i> , 2006, 34, 181-187.	0.2	1
658	New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. <i>Pharmacotherapy</i> , 2006, 26, 13S-31S.	1.2	9

#	ARTICLE	IF	CITATIONS
659	Novel "œplum pudding" gels as potential drug-eluting stent coatings: Controlled release of fluvastatin. <i>Journal of Biomedical Materials Research - Part A</i> , 2006, 79A, 923-933.	2.1	31
660	The Predictive Value of C-Reactive Protein in End-Stage Renal Disease: Is It Clinically Significant?. <i>Blood Purification</i> , 2006, 24, 335-341.	0.9	19
661	Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2006, 27, 2945-2955.	1.0	85
662	How and When Do We Alter Inflammatory Mechanisms in Stroke? Will It Help?. <i>Seminars in Neurology</i> , 2006, 26, 075-087.	0.5	1
663	Biomarkers of exposure and potential harm in adult smokers of 3"7 mg tar yield (Federal Trade) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.9	41
664	Therapy Insight: management of cardiovascular disease in the renal transplant recipient. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 514-526.	2.0	14
665	Atherosclerosis is an Inflammatory Disorder After All. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 93-102.	1.0	11
666	Novel Concepts of Statin Therapy for Cardiovascular Risk Reduction in Hypertension. <i>Current Pharmaceutical Design</i> , 2006, 12, 1593-1609.	0.9	16
667	Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications. <i>Current Cardiology Reviews</i> , 2006, 2, 173-184.	0.6	1
668	Statins And Biomarkers In Claudicants With Peripheral Arterial Disease: Cross-sectional Study. <i>Vascular</i> , 2006, 14, 193-200.	0.4	13
669	Statin Therapy for Native and Peri-Interventional Coronary Heart Disease. <i>Current Molecular Medicine</i> , 2006, 6, 589-602.	0.6	8
670	High Sensitivity C-Reactive Protein (hsCRP): A New Biochemical Marker of Atherosclerotic Vascular Disease. <i>Current Cardiology Reviews</i> , 2006, 2, 215-225.	0.6	0
671	Primary Prevention of Ischemic Stroke. <i>Stroke</i> , 2006, 37, 1583-1633.	1.0	1,100
672	Prevention of Positive Coronary Artery Remodeling with Statin Therapy in Patients with Coronary Artery Diseases. <i>Angiology</i> , 2006, 57, 259-265.	0.8	13
673	A 39-Year-Old Woman With Hypercholesterolemia. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 319.	3.8	0
674	Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. <i>Journal of Clinical Pathology</i> , 2006, 59, 196-201.	1.0	83
675	C-Reactive Protein as a Risk Predictor. <i>Circulation</i> , 2006, 114, e67-74.	1.6	68
676	Interleukin-18-induced Human Coronary Artery Smooth Muscle Cell Migration Is Dependent on NF-ÎB- and AP-1-mediated Matrix Metalloproteinase-9 Expression and Is Inhibited by Atorvastatin. <i>Journal of Biological Chemistry</i> , 2006, 281, 15099-15109.	1.6	179

#	ARTICLE	IF	CITATIONS
677	An Assessment of Incremental Coronary Risk Prediction Using C-Reactive Protein and Other Novel Risk Markers. <i>Archives of Internal Medicine</i> , 2006, 166, 1368.	4.3	323
678	Rethinking Primary Prevention of Atherosclerosis-Related Diseases. <i>Circulation</i> , 2006, 114, 2517-2527.	1.6	88
679	Handbook of Multiple Sclerosis. , 0, , .		9
680	C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention. , 2006, , 237-260.		1
681	Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators. <i>European Heart Journal</i> , 2006, 27, 700-707.	1.0	117
682	Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial. <i>Circulation</i> , 2006, 114, 281-288.	1.6	284
683	Stat3 Mediates Interleukin-6 Inhibition of Human Endothelial Nitric-oxide Synthase Expression. <i>Journal of Biological Chemistry</i> , 2006, 281, 30057-30062.	1.6	69
684	Wide Clinical Implementation of Insulin Resistance Syndrome?. <i>Metabolic Syndrome and Related Disorders</i> , 2006, 4, 165-171.	0.5	0
685	The importance of total cardiovascular risk assessment in clinical practice. <i>European Journal of General Practice</i> , 2006, 12, 148-155.	0.9	26
686	The effect of infections and vaccinations on stroke risk. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 175-183.	1.4	17
687	The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. <i>Pediatrics</i> , 2007, 119, 370-380.	1.0	58
688	Impact of C-reactive protein on treatment of patients with cardiovascular disease. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 2009-2016.	0.5	10
689	Pleiotropic Effects of Statins: Stabilization of the Vulnerable Atherosclerotic Plaque?. <i>Current Pharmaceutical Design</i> , 2007, 13, 1003-1012.	0.9	32
690	The Therapeutic Potential of Statins in Neurological Disorders. <i>Current Medicinal Chemistry</i> , 2007, 14, 103-112.	1.2	58
691	C-Reactive Protein and Asymmetric Dimethylarginine: Markers or Mediators in Cardiovascular Disorders?. <i>Current Pharmaceutical Design</i> , 2007, 13, 1619-1629.	0.9	12
692	The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose positron emission tomography. <i>European Heart Journal</i> , 2007, 28, 2243-2248.	1.0	111
693	Interaction between C-Reactive Protein and Endothelin-1 in Coronary Artery Disease. <i>Cardiology</i> , 2007, 107, 340-344.	0.6	4
694	CRP has little incremental value over traditional cardiovascular risk factors in risk stratification. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 290-291.	3.3	3

#	ARTICLE	IF	CITATIONS
695	Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. <i>Kidney International</i> , 2007, 72, 473-480.	2.6	84
696	Drug Insight: statins for nonischemic heart failure—evidence and potential mechanisms. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 196-205.	3.3	25
697	Coronary Heart Disease Syndromes: Pathophysiology and Clinical Recognition. , 2007, , 667-698.		1
698	Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease. <i>Circulation</i> , 2007, 115, 1528-1536.	1.6	316
699	Socioeconomic Position, Race/Ethnicity, and Inflammation in the Multi-Ethnic Study of Atherosclerosis. <i>Circulation</i> , 2007, 116, 2383-2390.	1.6	138
700	State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training. <i>American Journal of Lifestyle Medicine</i> , 2007, 1, 220-235.	0.8	98
701	The Relationship Between Plasma C-Reactive Protein Levels and Presence and Severity of Coronary Stenosis in Patients With Stable Angina. <i>Angiology</i> , 2007, 58, 657-662.	0.8	9
703	Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. <i>Biomarkers in Medicine</i> , 2007, 1, 229-241.	0.6	14
704	Upstream Therapy for Atrial Fibrillation. <i>Circulation Journal</i> , 2007, 71, A75-A81.	0.7	5
705	Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary findings. <i>Clinical Science</i> , 2007, 113, 443-448.	1.8	9
706	Evaluation of C-Reactive Protein in Primary and Secondary Prevention. <i>Journal of Investigative Medicine</i> , 2007, 55, 430-438.	0.7	8
707	C-Reactive Protein, Stroke, and Statins. <i>Critical Care Nursing Quarterly</i> , 2007, 30, 161-165.	0.4	7
708	Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. <i>Aids</i> , 2007, 21, 921-927.	1.0	118
709	Role of Hyperglycaemia in Pathogenesis of Diabetic Cardiovascular Disease. <i>Vascular Disease Prevention</i> , 2007, 4, 125-139.	0.2	0
710	Emerging Risk Factors for Cerebrovascular Disease. <i>Current Drug Targets</i> , 2007, 8, 802-816.	1.0	6
711	The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders. <i>Current Drug Targets</i> , 2007, 8, 247-256.	1.0	6
712	Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2007, 82, 301-307.	1.4	11
713	Measuring soluble CD40 ligand:interleukin-10 ratio as a prognostic marker in acute myocardial infarction: Yet another prognostic biomarker?. <i>Thrombosis Research</i> , 2007, 121, 289-291.	0.8	0

#	ARTICLE	IF	CITATIONS
714	Reduction of risk factors for cardiovascular diseases in African Americans with a 12-week nutrition education program. <i>Nutrition Research</i> , 2007, 27, 252-257.	1.3	17
715	Statins for the primary prevention of cardiovascular events in older adults: A review of the evidence. <i>American Journal of Geriatric Pharmacotherapy</i> , 2007, 5, 52-63.	3.0	32
716	Cloning, characterization, expression and comparative analysis of pig Golgi membrane sphingomyelin synthase 1. <i>Gene</i> , 2007, 388, 117-124.	1.0	14
717	C-reactive protein: a nontraditional serum marker of cardiovascular risk. <i>Cardiovascular Pathology</i> , 2007, 16, 14-21.	0.7	151
718	CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?. <i>International Journal of Cardiology</i> , 2007, 120, 108-114.	0.8	40
719	Establishing the benefit of statins in low-to-moderate risk primary prevention: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). <i>Atherosclerosis Supplements</i> , 2007, 8, 3-8.	1.2	13
720	Relationship Between Age-Related Macular Degeneration-Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2007, 82, 301-307.	1.4	17
721	Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study. <i>Current Medical Research and Opinion</i> , 2007, 23, 1821-1827.	0.9	7
722	A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. <i>European Heart Journal</i> , 2007, 28, 664-672.	1.0	115
723	Regression or Reduction in Progression of Atherosclerosis, and Avoidance of Coronary Events, With Lovastatin in Patients With or at High Risk of Cardiovascular Disease. <i>Clinical Drug Investigation</i> , 2007, 27, 591-604.	1.1	18
724	Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine. <i>Journal of the American College of Cardiology</i> , 2007, 49, 279-289.	1.2	27
725	Low-Density Lipoprotein-Dependent and -Independent Effects of Cholesterol-Lowering Therapies on C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2003-2009.	1.2	161
726	C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk. <i>Journal of the American College of Cardiology</i> , 2007, 49, 2129-2138.	1.2	520
727	Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis. <i>Journal of the American College of Cardiology</i> , 2007, 50, 852-858.	1.2	225
728	Primary Prevention of Ischemic Heart Disease. , 2007, , 178-220.		1
729	Statins. , 2007, , 1668-1673.		0
730	Non-Antiarrhythmic Drugs in Atrial Fibrillation: A Review of Non-Antiarrhythmic Agents in Prevention of Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 1222-1228.	0.8	26
731	Atherogenesis: the role of inflammation and infection. <i>Histopathology</i> , 2007, 50, 535-546.	1.6	84

#	ARTICLE	IF	CITATIONS
732	Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome. <i>Journal of Neurochemistry</i> , 2007, 100, 1265-1277.	2.1	39
733	C-reactive protein predicts further ischemic events in transient ischemic attack patients. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 60-66.	1.0	44
734	C-Reactive Protein and Aortic Stiffness in Patients with Idiopathic Dilated Cardiomyopathy. <i>Echocardiography</i> , 2007, 24, 1-8.	0.3	10
735	Potential Roles for Statins in Critically Ill Patients. <i>Pharmacotherapy</i> , 2007, 27, 1279-1296.	1.2	11
736	Comparison of Effects of High (80 mg) Versus Low (20 mg) Dose of Simvastatin on C-Reactive Protein and Lipoproteins in Patients With Angiographic Evidence of Coronary Arterial Narrowing. <i>American Journal of Cardiology</i> , 2007, 99, 149-153.	0.7	14
737	Role of C-Reactive Protein in Coronary Risk Reduction: Focus on Primary Prevention. <i>American Journal of Cardiology</i> , 2007, 99, 718-725.	0.7	38
738	Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>American Journal of Cardiology</i> , 2007, 100, 1659-1664.	0.7	113
739	Statins and the endothelium. <i>Vascular Pharmacology</i> , 2007, 46, 1-9.	1.0	110
740	Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. , 2007, 114, 107-126.		40
741	PON1, A New Biomarker of Cardiovascular Disease, Is Low in Patients with Systemic Vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2007, 37, 149-155.	1.6	14
742	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. <i>Journal of Neuroimmunology</i> , 2007, 184, 17-26.	1.1	42
744	Statins and biomarkers of inflammation. <i>Current Atherosclerosis Reports</i> , 2007, 9, 33-41.	2.0	62
745	The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 113-121.	0.8	41
746	The Effects of High Dose Pravastatin and Low Dose Pravastatin and Ezetimibe Combination Therapy on Lipid, Glucose Metabolism and Inflammation. <i>Inflammation</i> , 2007, 30, 230-235.	1.7	34
747	The Mechanism Underlying Vascular Smooth Muscle Cell Apoptosis Induced by Atorvastatin may be Mainly Associated with Down-regulation of Survivin Expression. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 145-153.	1.3	10
748	High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. <i>Journal of Gastroenterology</i> , 2007, 42, 573-582.	2.3	247
749	Mevalonate pathway: A review of clinical and therapeutical implications. <i>Clinical Biochemistry</i> , 2007, 40, 575-584.	0.8	471
750	Simvastatin Attenuates Trinitrobenzene Sulfonic Acid-Induced Colitis, but Not Oxazalone-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1869-1875.	1.1	30

#	ARTICLE	IF	CITATIONS
751	Using inflammatory biomarkers to guide lipid therapy. <i>Current Cardiovascular Risk Reports</i> , 2008, 2, 29-34.	0.8	3
752	Statins in liver disease: A molehill, an iceberg, or neither?. <i>Hepatology</i> , 2008, 48, 662-669.	3.6	117
753	Inflammatory Biomarkers and Risks of Myocardial Infarction, Stroke, Diabetes, and Total Mortality: Implications for Longevity. <i>Nutrition Reviews</i> , 2007, 65, S253-S259.	2.6	117
754	Effect of Statin Therapy Before Q-Wave Myocardial Infarction on Myocardial Perfusion. <i>American Journal of Cardiology</i> , 2008, 101, 139-143.	0.7	19
755	Risk Stratification and Prognostic Factors in the Post-Myocardial Infarction Patient. <i>American Journal of Cardiology</i> , 2008, 102, 13G-20G.	0.7	13
756	AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2008, 102, 1631-1643.	0.7	148
757	Plaque Biology: Interesting Science or Pharmacological Treasure Trove?. <i>European Journal of Vascular and Endovascular Surgery</i> , 2008, 36, 507-516.	0.8	10
758	Effects of C-reactive Protein and Homocysteine on Cytokine Production: Modulation by Pravastatin. <i>Archives of Drug Information</i> , 2008, 1, 14-22.	1.6	11
759	Contemporary Approach to the Diagnosis and Management of Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Progress in Cardiovascular Diseases</i> , 2008, 50, 311-351.	1.6	16
760	ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease. <i>Translational Research</i> , 2008, 152, 113-118.	2.2	27
761	Defining a Role for Novel Biomarkers in Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2008, 54, 1424-1431.	1.5	23
762	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>New England Journal of Medicine</i> , 2008, 359, 2195-2207.	13.9	5,712
763	The effects of short term statin treatment on left ventricular function and inflammatory markers in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2008, 123, 102-107.	0.8	61
764	Statins and inflammation: Reciprocal effectors to endothelial progenitors?. <i>Thrombosis Research</i> , 2008, 123, 1-4.	0.8	5
765	Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin) Trial. <i>Journal of the American College of Cardiology</i> , 2008, 51, 177-184.	1.5	177
766	Investigations of Statins in Heart Failure: Inflammatory Biomarkers and Hormones. <i>Heart Failure Clinics</i> , 2008, 4, 171-176.	1.0	0
767	Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein. <i>Mayo Clinic Proceedings</i> , 2008, 83, 333-342.	1.4	39
768	Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. <i>Clinical Chemistry</i> , 2008, 54, 24-38.	1.5	779

#	ARTICLE	IF	CITATIONS
769	Statins and sepsis. <i>British Journal of Anaesthesia</i> , 2008, 100, 288-298.	1.5	74
770	Dietary Cod Protein Reduces Plasma C-Reactive Protein in Insulin-Resistant Men and Women ³ . <i>Journal of Nutrition</i> , 2008, 138, 2386-2391.	1.3	83
771	Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. <i>Circulation</i> , 2008, 117, 163-168.	1.6	697
772	The use of high-sensitivity assays for C-reactive protein in clinical practice. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 621-635.	3.3	123
773	Simvastatin Inhibits Catecholamine Secretion and Synthesis Induced by Acetylcholine via Blocking Na ⁺ and Ca ²⁺ Influx in Bovine Adrenal Medullary Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 130-136.	1.3	11
774	Cardiovascular disease – the silent killer in rheumatoid arthritis. <i>Clinical Medicine</i> , 2008, 8, 384-387.	0.8	15
775	Principles of Clinical Medicine for Space Flight. , 2008, , .		82
776	Cardiovascular Disorders. , 2008, , 317-359.		13
777	Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia. <i>Angiology</i> , 2008, 59, 542-548.	0.8	17
778	Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. <i>Lupus</i> , 2008, 17, 114-123.	0.8	23
779	Pre-Operative Atorvastatin Therapy to Decrease the Systemic Inflammatory Response after Coronary Artery Bypass Grafting. <i>Journal of International Medical Research</i> , 2008, 36, 1248-1254.	0.4	23
780	Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. <i>Kidney International</i> , 2008, 74, 1461-1467.	2.6	71
781	Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acids. <i>Upsala Journal of Medical Sciences</i> , 2008, 113, 315-324.	0.4	9
782	The Time for Cardiovascular Inflammation Reduction Trials Has Arrived. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1222-1224.	1.1	23
783	C-Reactive Protein. , 0, , 159-180.		0
784	A Study of the High-sensitive CRP Level in Sudden Deafness. <i>Practica Otologica</i> , 2008, 101, 829-833.	0.0	0
785	Natriuretic Peptides and Inflammatory Markers for Risk Stratification in Patients with Ischemic Heart Disease. , 0, , 53-74.		1
786	Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum. <i>Current Pharmaceutical Design</i> , 2008, 14, 2445-2461.	0.9	11

#	ARTICLE	IF	CITATIONS
787	The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , 2008, 14, 2605-2612.	0.9	7
788	An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease. <i>Biomarker Insights</i> , 2008, 3, BMI.S480.	1.0	27
789	Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study. <i>American Journal of Clinical Nutrition</i> , 2008, 88, 630-637.	2.2	57
790	Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. <i>Biomarker Insights</i> , 2008, 3, 117727190800300.	1.0	2
791	Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigators. <i>Journal of Atherosclerosis and Thrombosis</i> , 2008, 15, 345-350.	0.9	41
792	New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor. <i>Clinical Interventions in Aging</i> , 2008, Volume 3, 341-349.	1.3	30
793	Avalia�o do grau de inflama�o vascular em pacientes com s�ndrome metab�lica. <i>Arquivos Brasileiros De Cardiologia</i> , 2009, 93, 360-366.	0.3	11
794	Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. <i>Vascular Health and Risk Management</i> , 2009, 5, 369.	1.0	23
795	Effects of Pitavastatin on Serum Lipids and High Sensitivity C-Reactive Protein in Type 2 Diabetic Patients. <i>Journal of Atherosclerosis and Thrombosis</i> , 2009, 16, 546-552.	0.9	20
797	Prognostic Biomarkers in Individuals with Prevalent Coronary Heart Disease. <i>Disease Markers</i> , 2009, 26, 265-271.	0.6	8
798	Aging and DNA Methylation. <i>Current Chemical Biology</i> , 2009, 3, 1-9.	0.2	5
799	The JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequences. <i>Vascular Health and Risk Management</i> , 2009, 5, 1033.	1.0	16
800	Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 616-623.	0.9	128
801	Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 503-512.	1.4	27
802	The Clinical Utility of High-Sensitivity C-Reactive Protein in Cardiovascular Disease and the Potential Implication of JUPITER on Current Practice Guidelines. <i>Clinical Chemistry</i> , 2009, 55, 219-228.	1.5	86
803	Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study. <i>Clinical Chemistry</i> , 2009, 55, 305-312.	1.5	82
804	Cardiovascular disease in patients with renal disease: the role of statins. <i>Current Medical Research and Opinion</i> , 2009, 25, 271-285.	0.9	34
805	C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease. <i>Clinical Chemistry</i> , 2009, 55, 209-215.	1.5	156

#	ARTICLE	IF	CITATIONS
806	From Here to JUPITER. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 41-48.	0.9	48
807	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	37
808	Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk. <i>Future Cardiology</i> , 2009, 5, 231-236.	0.5	7
809	Myocardial Infarction in a 72-Year-Old Woman with Low LDL-C and Increased hsCRP: Implications for Statin Therapy. <i>Clinical Chemistry</i> , 2009, 55, 369-374.	1.5	4
810	Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009, 297, H2004-H2014.	1.5	74
811	Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis. <i>Journal of Lipid Research</i> , 2009, 50, S352-S357.	2.0	104
812	The JUPITER Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 279-285.	0.9	119
813	Standardized capsule of <i>Camellia sinensis</i> lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study. <i>Nutrition</i> , 2009, 25, 147-154.	1.1	98
814	Novel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease. <i>Progress in Cardiovascular Diseases</i> , 2009, 51, 503-523.	1.6	23
815	Inflammatory biomarkers in coronary artery disease. <i>Journal of Cardiology</i> , 2009, 53, 317-333.	0.8	275
816	Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 332-339.	1.9	252
817	The Editor's Roundtable: The JUPITER Trial's Initial Results and Clinical Implications. <i>American Journal of Cardiology</i> , 2009, 103, 1417-1425.	0.7	19
818	Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension—Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Mai. <i>American Journal of Cardiology</i> , 2009, 104, 868-872.	0.7	229
819	Vitamin C treatment reduces elevated C-reactive protein. <i>Free Radical Biology and Medicine</i> , 2009, 46, 70-77.	1.3	92
820	El control del colesterol en prevenci3n primaria. ¿Cuanto m3s bajo, mejor?. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2009, 16, 449-451.	0.0	0
821	Should patients with rheumatoid arthritis receive statin therapy?. <i>Arthritis and Rheumatism</i> , 2009, 60, 1205-1209.	6.7	21
822	Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. <i>Endocrine</i> , 2009, 35, 380-388.	1.1	12
823	Justification for the use of statins in primary prevention: An intervention trial evaluating rosuvastatin (the JUPITER trial). <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 83-85.	0.8	2

#	ARTICLE	IF	CITATIONS
824	Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. <i>Current Atherosclerosis Reports</i> , 2009, 11, 243-244.	2.0	13
825	Moving toward new statin guidelines in a post-JUPITER world: Principles to consider. <i>Current Atherosclerosis Reports</i> , 2009, 11, 249-256.	2.0	18
826	Statin therapy, inflammation, and risk for cardiovascular events: The light from JUPITER is illuminating. <i>Current Atherosclerosis Reports</i> , 2009, 11, 323-325.	2.0	0
827	The Jupiter trial: Key findings, controversies, and implications. <i>Current Cardiology Reports</i> , 2009, 11, 81-82.	1.3	6
828	Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. <i>Advances in Therapy</i> , 2009, 26, 469-487.	1.3	13
829	Validated treatments and therapeutics perspectives regarding pharmacological products for sarcopenia. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 746-756.	1.5	34
830	CRP in Cardiovascular Disease. <i>Herz</i> , 2009, 34, 607-613.	0.4	41
831	Innate and adaptive immunity in atherosclerosis. <i>Seminars in Immunopathology</i> , 2009, 31, 5-22.	2.8	154
832	Regulation of different inflammatory diseases by impacting the mevalonate pathway. <i>Immunology</i> , 2009, 127, 18-25.	2.0	35
833	SEARCHing for JUPITER: starry-eyed optimism is not warranted. <i>International Journal of Clinical Practice</i> , 2009, 63, 685-688.	0.8	5
834	Hot and bothered: C-reactive protein, inflammation and atherosclerosis. <i>International Journal of Clinical Practice</i> , 2009, 63, 1550-1553.	0.8	5
835	(TTA) _n Polymorphism in 3- α -Hydroxy- β -Methylglutaryl-Coenzyme A and Response to Atorvastatin in Coronary Artery Disease Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 211-215.	1.2	7
836	Are We All Hypo-Statinaemics?. <i>International Journal of Stroke</i> , 2009, 4, 185-186.	2.9	0
837	The role of pioglitazone in modifying the atherogenic lipoprotein profile. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 742-756.	2.2	26
838	HOCHUEKKITO IMPROVES SYSTEMIC INFLAMMATION AND NUTRITIONAL STATUS IN ELDERLY PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 169-170.	1.3	74
839	BODY MASS INDEX: PITFALLS IN ELDERLY PEOPLE. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 170-172.	1.3	10
840	Cardiac biomarkers and the case for point-of-care testing. <i>Clinical Biochemistry</i> , 2009, 42, 549-561.	0.8	227
841	Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. <i>Clinical Biochemistry</i> , 2009, 42, 1331-1346.	0.8	359

#	ARTICLE	IF	CITATIONS
842	Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 1041-1056.	0.6	12
843	To assess, to control, to exclude: Effects of biobehavioral factors on circulating inflammatory markers. <i>Brain, Behavior, and Immunity</i> , 2009, 23, 887-897.	2.0	415
844	Lipids, atherosclerosis and CVD risk: Is CRP an innocent bystander?. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 521-524.	1.1	78
845	Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2009, 674, 93-100.	0.9	56
846	Effect of Statin Adherence on Cerebrovascular Disease in Primary Prevention. <i>American Journal of Medicine</i> , 2009, 122, 647-655.	0.6	56
847	The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2039-2050.	1.2	359
848	Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 2009, 54, 2388-2395.	1.2	49
849	Obesity, inflammation, and atherosclerosis. <i>Nature Reviews Cardiology</i> , 2009, 6, 399-409.	6.1	779
850	Markers of Inflammation and Cardiovascular Disease. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 3-7.	1.0	13
851	Ezetimibe/simvastatin. <i>Expert Opinion on Drug Safety</i> , 2009, 8, 715-725.	1.0	8
852	Statin research in critical illness: hampered by poor trial design?. <i>Critical Care</i> , 2009, 13, 1015.	2.5	1
853	Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. <i>Atherosclerosis</i> , 2009, 202, 282-288.	0.4	39
854	Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. <i>Atherosclerosis</i> , 2009, 202, 550-556.	0.4	34
855	The vascular risk associations with migraine: Relation to migraine susceptibility and progression. <i>Atherosclerosis</i> , 2009, 205, 15-22.	0.4	47
858	Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results. <i>Canadian Journal of Cardiology</i> , 2009, 25, e236-e240.	0.8	15
859	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. <i>Lancet, The</i> , 2009, 373, 1175-1182.	6.3	886
860	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial â€“ Authors' reply. <i>Lancet, The</i> , 2009, 374, 26-27.	6.3	2
861	Inflammation in Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2009, 54, 2129-2138.	1.2	1,738

#	ARTICLE	IF	CITATIONS
862	Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease. <i>Mayo Clinic Proceedings</i> , 2009, 84, 345-352.	1.4	28
863	Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). <i>Circulation</i> , 2009, 120, 2188-2196.	1.6	155
864	Interferon and Heart Disease. <i>Critical Care Nursing Quarterly</i> , 2009, 32, 159-162.	0.4	5
865	Effect of Chronic Statin Pretreatment on Hospital Outcome in Patients With Acute Non-ST-Elevation Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 132-136.	0.8	17
866	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2009, 20, 262-263.	1.2	0
867	A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery. <i>Yearbook of Cardiology</i> , 2009, 2009, 284-286.	0.0	0
868	Chapter 3 Effect of Hormone Replacement Therapy on Inflammatory Biomarkers. <i>Advances in Clinical Chemistry</i> , 2009, 47, 59-93.	1.8	34
869	C-Reactive Protein and Cardiovascular Diseases—Is it Ready for Primetime?. <i>American Journal of the Medical Sciences</i> , 2009, 338, 486-492.	0.4	74
870	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. <i>Yearbook of Cardiology</i> , 2009, 2009, 282-284.	0.0	0
871	Pleiotropic Effects of Statins - Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2009, 15, 479-489.	0.9	144
872	Aging and DNA Methylation. <i>Current Chemical Biology</i> , 2009, 3, 321-329.	0.2	5
873	The Connection Between C-Reactive Protein (CRP) and Diabetic Vasculopathy. Focus on Preclinical Findings. <i>Current Diabetes Reviews</i> , 2010, 6, 27-34.	0.6	78
874	Statins and Ischaemia Reperfusion Injury: A Molecular Biological Review. <i>Current Vascular Pharmacology</i> , 2010, 8, 831-835.	0.8	6
875	Clinical implications of inflammation for cardiovascular primary prevention. <i>European Heart Journal</i> , 2010, 31, 777-783.	1.0	81
876	Statins and inflammation: an update. <i>Current Opinion in Cardiology</i> , 2010, 25, 399-405.	0.8	92
878	An Update on the Role of Markers of Inflammation in Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 1-11.	0.9	169
879	Should We Measure C-reactive Protein on Earth or Just on JUPITER?. <i>Clinical Cardiology</i> , 2010, 33, 190-198.	0.7	20
882	Targeting inflammation to slow or delay functional decline: where are we?. <i>Biogerontology</i> , 2010, 11, 603-614.	2.0	29

#	ARTICLE	IF	CITATIONS
883	Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin Treatment. <i>Current Atherosclerosis Reports</i> , 2010, 12, 34-42.	2.0	16
884	New Evidence Extending the Benefit of Treating LDL-C Beyond the Current Guidelines. <i>Current Atherosclerosis Reports</i> , 2010, 12, 1-4.	2.0	0
885	Adding exercise to rosuvastatin treatment: influence on C-reactive protein, monocyte toll-like receptor 4 expression, and inflammatory monocyte (CD14+CD16+) population. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1775-1783.	1.5	37
886	Sex difference in the association of metabolic syndrome with high sensitivity C-reactive protein in a Taiwanese population. <i>BMC Public Health</i> , 2010, 10, 429.	1.2	32
887	Relation Between C-Reactive Protein, Homocysteine Levels, Fibrinogen, and Lipoprotein Levels and Leukocyte and Platelet Counts, and 10-Year Risk for Cardiovascular Disease Among Healthy Adults in the USA. <i>American Journal of Cardiology</i> , 2010, 105, 1284-1288.	0.7	61
888	Relation of C-Reactive Protein to Abdominal Adiposity. <i>American Journal of Cardiology</i> , 2010, 106, 56-61.	0.7	194
889	The JUPITER Trial: Responding to the Critics. <i>American Journal of Cardiology</i> , 2010, 106, 1351-1356.	0.7	29
890	Short-Term Treatment with High-Dose Atorvastatin Reduces LDL Cholesterol but Shows no Anti-Inflammatory Effects in Normolipidemic Subjects with Normal CRP Levels. <i>Clinical and Translational Science</i> , 2010, 3, 140-146.	1.5	14
891	Single nucleotide polymorphism rs2229634 in the <i>ITPR3</i> gene is associated with the risk of developing coronary artery aneurysm in children with Kawasaki disease. <i>International Journal of Immunogenetics</i> , 2010, 37, 439-443.	0.8	31
892	The Levels of Inflammatory Markers in the Treatment of Stroke Study (Limits): Inflammatory Biomarkers as Risk Predictors after Lacunar Stroke. <i>International Journal of Stroke</i> , 2010, 5, 117-125.	2.9	44
893	Practice makes perfect: reflections on a primary care treatment-to-target study. <i>International Journal of Clinical Practice</i> , 2010, 64, 1006-1008.	0.8	4
894	Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 85-94.	1.1	27
895	C-reactive protein lowering with rosuvastatin in the METEOR study. <i>Journal of Internal Medicine</i> , 2010, 268, 155-161.	2.7	29
896	Novel non-invasive approach for visualizing inflamed atherosclerotic plaques using fluorodeoxyglucose-positron emission tomography. <i>Geriatrics and Gerontology International</i> , 2010, 10, 1-8.	0.7	23
897	Effects of fluvastatin therapy on serum interleukin-18 and interleukin-10 levels in patients with acute coronary syndrome. <i>Acta Cardiologica</i> , 2010, 65, 285-289.	0.3	13
898	Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective. <i>Drug Design, Development and Therapy</i> , 2010, 4, 383.	2.0	91
899	Statin Therapy for Low-LDL, High-hsCRP Patients: From JUPITER to CORONA. <i>Clinical Chemistry</i> , 2010, 56, 505-507.	1.5	9
900	Inflammation in Atherosclerosis: Transition From Theory to Practice. <i>Circulation Journal</i> , 2010, 74, 213-220.	0.7	623

#	ARTICLE	IF	CITATIONS
901	Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 447-452.	0.9	52
902	STUDY OF NANOPOROUS MEMBRANES WITH APPLICATIONS IN THE ENHANCED DETECTION OF CADIOVASCULAR BIOMARKER PROTEINS. <i>Nano LIFE</i> , 2010, 01, 175-183.	0.6	7
903	Targeting Patients for Statin Therapy for the Primary Prevention of Vascular Events: What is the Best Approach?. <i>Circulation</i> , 2010, 122, 1446-1448.	1.6	2
904	Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1685-1691.	1.4	62
905	Cost-Effectiveness of Using High-Sensitivity C-Reactive Protein to Identify Intermediate- and Low-Cardiovascular-Risk Individuals for Statin Therapy. <i>Circulation</i> , 2010, 122, 1478-1487.	1.6	59
906	A Review of Perioperative Statin Therapy for Noncardiac Surgery. <i>Seminars in Cardiothoracic and Vascular Anesthesia</i> , 2010, 14, 283-290.	0.4	15
907	Prehypertension Subtype With Elevated C-Reactive Protein: Risk of Ischemic Stroke in a General Japanese Population. <i>American Journal of Hypertension</i> , 2010, 23, 1108-1113.	1.0	24
908	Measuring hsCRP—An Important Part of a Comprehensive Risk Profile or a Clinically Redundant Practice?. <i>PLoS Medicine</i> , 2010, 7, e1000196.	3.9	15
909	By Jove! What Is a Clinician to Make of JUPITER?. <i>Archives of Internal Medicine</i> , 2010, 170, 1073.	4.3	59
910	Contemporary Results of Carotid Endarterectomy for Asymptomatic Carotid Stenosis. <i>Stroke</i> , 2010, 41, 975-979.	1.0	52
911	Adjuvant therapy for atrial fibrillation. <i>Future Cardiology</i> , 2010, 6, 67-81.	0.5	6
912	Clinical Implications of the Cytokine Hypothesis of Depression: The Association between Use of Statins and Aspirin and the Risk of Major Depression. <i>Psychotherapy and Psychosomatics</i> , 2010, 79, 323-325.	4.0	82
913	Pleiotropic Effects of Statins. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 3-9.	1.0	52
914	Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1266-1273.	1.2	191
915	More Progression Toward Regression?. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2743-2744.	1.2	1
916	New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery. <i>Journal of Vascular Surgery</i> , 2010, 51, 242-251.	0.6	59
917	Pharmacological modulation of vascular inflammation in atherothrombosis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1207, 23-31.	1.8	21
918	Rosuvastatin. <i>American Journal of Cardiovascular Drugs</i> , 2010, 10, 383-400.	1.0	14

#	ARTICLE	IF	CITATIONS
919	To JUPITER and beyond: Statins, inflammation, and primary prevention. <i>Critical Care</i> , 2010, 14, 310.	2.5	12
920	Chronic immune stimulation as a contributing cause of chronic disease in opiate addiction including multi-system ageing. <i>Medical Hypotheses</i> , 2010, 75, 613-619.	0.8	16
921	Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. <i>International Journal of Cardiology</i> , 2010, 142, 257-264.	0.8	14
922	Statins in community acquired pneumonia: Evidence from experimental and clinical studies. <i>Respiratory Medicine</i> , 2010, 104, 1081-1091.	1.3	69
923	C-reactive protein and cardiovascular risk: more fuel to the fire. <i>Lancet, The</i> , 2010, 375, 95-96.	6.3	21
924	C-reactive protein is a mediator of cardiovascular disease. <i>European Heart Journal</i> , 2010, 31, 2087-2091.	1.0	164
925	Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. <i>Vascular and Endovascular Surgery</i> , 2010, 44, 241-251.	0.3	121
926	Physiopathologie de la maladie athéro-thrombotique: quelques données fondamentales pour comprendre le risque résiduel. <i>Medecine Des Maladies Metaboliques</i> , 2010, 4, 361-368.	0.1	0
927	Statin Prescribing in the Elderly in the Netherlands. <i>Drugs and Aging</i> , 2010, 27, 589-596.	1.3	34
928	Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. <i>Metabolic Syndrome and Related Disorders</i> , 2010, 8, 465-469.	0.5	5
929	Prognostic value, clinical effectiveness, and cost-effectiveness of high-sensitivity C-reactive protein as a marker for major cardiac events in asymptomatic individuals: A health technology assessment report. <i>International Journal of Technology Assessment in Health Care</i> , 2010, 26, 30-39.	0.2	16
930	Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 411-421.	0.6	41
931	C-reactive protein in rheumatology: biology and genetics. <i>Nature Reviews Rheumatology</i> , 2011, 7, 282-289.	3.5	149
932	Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia. <i>Annals of Pharmacotherapy</i> , 2011, 45, 841-849.	0.9	20
933	The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels. <i>Journal of the American College of Cardiology</i> , 2011, 57, 784-791.	1.2	38
934	Personalized Therapy Following Drug-Eluting Stenting Using Platelet Function Testing and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2640-2641.	1.2	0
935	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
936	Comprehensive Cardiovascular Medicine in the Primary Care Setting. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
938	Statins, inflammation and kidney disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 385-397.	4.1	72
939	Interleukin-1 β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). <i>American Heart Journal</i> , 2011, 162, 597-605.	1.2	728
940	Effects of statin therapy on non-calcified coronary plaque assessed by 64-slice computed tomography. <i>International Journal of Cardiology</i> , 2011, 150, 146-150.	0.8	20
941	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2011, 21, 213-221.	1.1	66
942	Statins for the primary prevention of cardiovascular disease. , 2011, , CD004816.		204
943	Pitavastatin: An overview. <i>Atherosclerosis Supplements</i> , 2011, 12, 271-276.	1.2	48
944	C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20â€™536 patients in the Heart Protection Study. <i>Lancet, The</i> , 2011, 377, 469-476.	6.3	154
945	Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. <i>Drug Design, Development and Therapy</i> , 2011, 5, 325.	2.0	201
946	Contrast-induced nephropathy: do statins offer protection?. <i>Current Opinion in Cardiology</i> , 2011, 26, 334-337.	0.8	5
947	Pathophysiology of Atherosclerosis: The Role of Inflammation. <i>Current Pharmaceutical Design</i> , 2011, 17, 4089-4110.	0.9	96
948	Effects of niacin on atherosclerosis and vascular function. <i>Current Opinion in Cardiology</i> , 2011, 26, 66-70.	0.8	27
949	Treatment with w-3 fatty acids reduces serum C-reactive protein concentration. <i>Clinical Lipidology</i> , 2011, 6, 723-729.	0.4	6
950	Statins in non-ischæmic cardiomyopathy: an update on our current clinical and pathophysiological understanding. <i>International Journal of Clinical Practice</i> , 2011, 65, 1156-1164.	0.8	6
951	Anti-inflammatory therapeutics for the treatment of atherosclerosis. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 365-376.	21.5	246
952	Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 994-1004.	1.6	68
953	Influence and Critique of the JUPITER Trial (Statins v No Statins for Primary Prevention of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Vascular Surgery, 2011, 24, 172-179.	1.1	4
954	Statins: A potential role in the management of osteoarthritis?. <i>Joint Bone Spine</i> , 2011, 78, 31-34.	0.8	32
955	Impact of Chronic Pre-Treatment of Statins on the Level of Systemic Inflammation and Myocardial Perfusion in Patients Undergoing Primary Angioplasty. <i>American Journal of Cardiology</i> , 2011, 107, 179-185.	0.7	30

#	ARTICLE	IF	CITATIONS
956	The Editor's Roundtable: Closing the Clinical Practice Gap—Using Evidence-Based Treatments for Managing Lipids. <i>American Journal of Cardiology</i> , 2011, 107, 230-242.	0.7	1
957	Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose. <i>American Journal of Cardiology</i> , 2011, 108, 3B-24B.	0.7	254
958	A two-step genetic study on quantitative precursors of coronary artery disease in a homogeneous Indian population: Case-control association discovery and validation by transmission-disequilibrium test. <i>Journal of Biosciences</i> , 2011, 36, 857-868.	0.5	5
959	Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study. <i>Netherlands Heart Journal</i> , 2011, 19, 17-23.	0.3	13
960	C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 545-549.	1.3	6
961	Les statines: un rôle possible dans le traitement de l'arthrose? <i>Revue Du Rhumatisme (Edition) Tj ETQq1 1 0,784314 rgBT /Over</i>	0.0	1
962	Uptake of F-18 FDG and ultrasound analysis of carotid plaque. <i>Journal of Nuclear Cardiology</i> , 2011, 18, 267-272.	1.4	23
963	The Role of C-Reactive Protein as a Risk Predictor of Coronary Atherosclerosis: Implications from the JUPITER Trial. <i>Current Atherosclerosis Reports</i> , 2011, 13, 154-161.	2.0	40
964	Design of cohort studies in chronic diseases using routinely collected databases when a prescription is used as surrogate outcome. <i>BMC Medical Research Methodology</i> , 2011, 11, 36.	1.4	5
965	Monitoring of inflammation in patients on dialysis: forewarned is forearmed. <i>Nature Reviews Nephrology</i> , 2011, 7, 166-176.	4.1	106
966	Designing better nano biosensors: Role of pore confinement of biomolecules. , 2011, , .		1
967	Oxidative stress and endothelial dysfunction: Therapeutic implications. <i>Annals of Medicine</i> , 2011, 43, 259-272.	1.5	104
968	Should C-Reactive Protein Be a Target of Therapy?. <i>Diabetes Care</i> , 2011, 34, S155-S160.	4.3	24
969	Lipid-lowering Drug Therapy in Elderly Patients. <i>Current Pharmaceutical Design</i> , 2011, 17, 877-893.	0.9	29
970	Physical Activity, High-Sensitivity C-Reactive Protein, and Total and Cardiovascular Disease Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 1492-1496.	4.3	32
971	High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. <i>Heart</i> , 2011, 97, 626-631.	1.2	13
972	Statins as Anti-inflammatory Therapy in HIV Disease?. <i>Journal of Infectious Diseases</i> , 2011, 203, 751-752.	1.9	8
973	Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. <i>Journal of Hypertension</i> , 2011, 29, 1757-1764.	0.3	31

#	ARTICLE	IF	CITATIONS
974	Hyperlipidemia in Primary Care. , 2011, , .		2
975	Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice. Current Pharmaceutical Design, 2011, 17, 4132-4146.	0.9	47
976	Lupus Atherosclerosis Prevention Study (LAPS). Annals of the Rheumatic Diseases, 2011, 70, 760-765.	0.5	194
977	Evaluating the Clinical Utility of a Biomarker. Circulation, 2011, 123, 1116-1124.	1.6	116
978	Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1316-1325.	2.2	116
979	Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients. Journal of Pharmacology and Pharmacotherapeutics, 2011, 2, 261-265.	0.2	10
980	The Effect of Aspirin on C-Reactive Protein in Hypertensive Patients. Clinical and Experimental Hypertension, 2011, 33, 47-52.	0.5	13
981	Cholesterol, Cytokines and Diseases. International Journal of Immunopathology and Pharmacology, 2011, 24, 567-581.	1.0	21
982	C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome. Heart Views, 2012, 13, 7.	0.1	29
983	Determinants of coronary collateral circulation in patients with coronary artery disease. Anatolian Journal of Cardiology, 2012, 13, 146-51.	0.4	15
984	Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials. PLoS ONE, 2012, 7, e34450.	1.1	78
985	A multiple biomarker risk score for guiding clinical decisions using a decision curve approach. European Journal of Preventive Cardiology, 2012, 19, 874-884.	0.8	12
986	C-Reactive Protein and the Framingham Coronary Risk Score in Patients Newly Diagnosed With Intermittent Claudication. Vascular and Endovascular Surgery, 2012, 46, 242-245.	0.3	3
987	CVD screening in low-risk, asymptomatic adults: clinical trials needed. Nature Reviews Cardiology, 2012, 9, 599-604.	6.1	38
988	Modulation of H ₂ S Metabolism by Statins: A New Aspect of Cardiovascular Pharmacology. Antioxidants and Redox Signaling, 2012, 17, 81-94.	2.5	27
989	Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active <i>Lactobacillus reuteri</i> NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. British Journal of Nutrition, 2012, 107, 1505-1513.	1.2	246
990	Pharmacogenetic Determinants of Statin-Induced Reductions in C-Reactive Protein. Circulation: Cardiovascular Genetics, 2012, 5, 58-65.	5.1	33
991	Fasting Serum C-peptide Levels Predict Cardiovascular and Overall Death in Nondiabetic Adults. Journal of the American Heart Association, 2012, 1, e003152.	1.6	72

#	ARTICLE	IF	CITATIONS
992	Targeting Endogenous Antioxidants to Prevent Cardiovascular Diseases. <i>Journal of the American Heart Association</i> , 2012, 1, e005215.	1.6	0
993	Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention. <i>International Journal of Occupational and Environmental Health</i> , 2012, 18, 70-78.	1.2	3
995	Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials. <i>European Heart Journal</i> , 2012, 33, 430-432.	1.0	59
996	Role of C-Reactive Protein in Acute Myocardial Infarction and Stroke: Possible Therapeutic Approaches. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 4-16.	0.9	55
997	CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease – IVUS substudy of the ENCORE trials. <i>Atherosclerosis</i> , 2012, 220, 172-176.	0.4	21
998	High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2012, 31, 733-745.	0.2	41
999	Lercanidipine Effect on Polymorphonuclear Leukocyte-Related Inflammation and Insulin Resistance in Essential Hypertension Patients. <i>Cardiology and Therapy</i> , 2012, 1, 4.	1.1	4
1000	Statins and other agents for vascular inflammation. <i>Journal of Vascular Surgery</i> , 2012, 56, 1799-1806.	0.6	11
1001	American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. <i>Endocrine Practice</i> , 2012, 18, 1-78.	1.1	386
1002	Developing and assessing cardiovascular biomarkers. <i>Translational Research</i> , 2012, 159, 265-276.	2.2	24
1003	Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease?. <i>European Heart Journal</i> , 2012, 33, 2258-2264.	1.0	14
1004	Comparative Effectiveness of 2 β -Blockers in Hypertensive Patients. <i>Archives of Internal Medicine</i> , 2012, 172, 1406.	4.3	11
1005	One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2012, 110, 356-363.	0.7	219
1006	Red Cell Distribution Width (RDW): A novel risk factor for cardiovascular disease. <i>International Journal of Cardiology</i> , 2012, 154, 351-352.	0.8	32
1007	Inflammation in Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2045-2051.	1.1	1,854
1008	Coronary Artery Calcium Scanning Should be Used for Primary Prevention. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 111-118.	2.3	22
1009	Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2384-2390.	1.2	277
1010	Comparison of the effects of 52 weeks weight loss with either a high-protein or high-carbohydrate diet on body composition and cardiometabolic risk factors in overweight and obese males. <i>Nutrition and Diabetes</i> , 2012, 2, e40-e40.	1.5	49

#	ARTICLE	IF	CITATIONS
1011	Biomarkers in Cardiovascular Clinical Trials: Past, Present, Future. <i>Clinical Chemistry</i> , 2012, 58, 45-53.	1.5	35
1012	Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: The PREMIUM Study. <i>Journal of Cardiology</i> , 2012, 60, 389-394.	0.8	25
1014	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events. <i>BioDrugs</i> , 2012, 26, 217-233.	2.2	65
1015	Plasma Cathepsin S and Cystatin C Levels and Risk of Abdominal Aortic Aneurysm: A Randomized Population-Based Study. <i>PLoS ONE</i> , 2012, 7, e41813.	1.1	46
1016	Effect of Modest Caloric Restriction on Oxidative Stress in Women, a Randomized Trial. <i>PLoS ONE</i> , 2012, 7, e47079.	1.1	45
1017	The Role and Clinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease. <i>Korean Circulation Journal</i> , 2012, 42, 151.	0.7	23
1018	The Effect of Doubling the Statin Dose on Pro-Inflammatory Cytokine in Patients With Triple-Vessel Coronary Artery Disease. <i>Korean Circulation Journal</i> , 2012, 42, 595.	0.7	5
1019	Lipid levels do not influence the risk of venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2012, 108, 923-929.	1.8	32
1020	Usefulness of Admission Red Cell Distribution Width as a Predictor of Early Mortality in Patients With Acute Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2012, 109, 128-134.	0.7	173
1021	Recent Clinical Studies of the Effects of Lipid-Modifying Therapies. <i>American Journal of Cardiology</i> , 2012, 110, 15A-26A.	0.7	36
1022	Role of C-Reactive Protein When Prescribing a Statin. <i>Current Atherosclerosis Reports</i> , 2012, 14, 26-32.	2.0	2
1023	Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. <i>Lipids in Health and Disease</i> , 2013, 12, 9.	1.2	21
1024	C-reactive protein and the biology of disease. <i>Immunologic Research</i> , 2013, 56, 131-142.	1.3	254
1025	High-Sensitivity C-Reactive Protein and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 397-408.	1.2	399
1026	Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies. <i>American Journal of Cardiovascular Drugs</i> , 2013, 13, 37-46.	1.0	119
1027	High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. <i>International Journal of Cardiology</i> , 2013, 168, 5126-5134.	0.8	240
1028	Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. <i>American Heart Journal</i> , 2013, 166, 199-207.e15.	1.2	347
1029	Pathophysiological Roles and Clinical Importance of Biomarkers in Acute Coronary Syndrome. <i>Advances in Clinical Chemistry</i> , 2013, 59, 23-63.	1.8	11

#	ARTICLE	IF	CITATIONS
1030	Inflammation and Atherosclerosis: Disease Modulating Therapies. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 681-695.	0.4	10
1031	Monocytes in Coronary Artery Disease and Atherosclerosis. Journal of the American College of Cardiology, 2013, 62, 1541-1551.	1.2	316
1032	C-reactive protein and incident diabetes in patients with arterial disease. European Journal of Clinical Investigation, 2013, 43, 1052-1059.	1.7	7
1033	Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. European Heart Journal, 2013, 34, 1350-1357.	1.0	4
1034	Inflammation and coagulation in atherosclerosis. Hamostaseologie, 2013, 33, 269-282.	0.9	36
1035	Assessment of inflammation in large arteries with 18F-FDG-PET in elderly. Computerized Medical Imaging and Graphics, 2013, 37, 459-465.	3.5	10
1036	The prognostic value of very low admission LDL-cholesterol levels in ST-segment elevation myocardial infarction compared in statin-pretreated and statin-naïve patients undergoing primary percutaneous coronary intervention. International Journal of Cardiology, 2013, 167, 458-463.	0.8	20
1037	Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis, 2013, 226, 466-470.	0.4	9
1038	Usefulness of Cardiac Biomarker Score for Risk Stratification in Stable Patients Undergoing Elective Cardiac Evaluation Across Glycemic Status. American Journal of Cardiology, 2013, 111, 465-470.	0.7	15
1039	ASK NOT What CRP Can Do for You. Journal of the American College of Cardiology, 2013, 62, 730-731.	1.2	2
1040	Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates?. Current Atherosclerosis Reports, 2013, 15, 295.	2.0	72
1041	The Evolution or Revolution of Statin Therapy in Primary Prevention: Where Do We Go From Here?. Current Atherosclerosis Reports, 2013, 15, 298.	2.0	5
1042	Factors determining high-sensitivity C-reactive protein values in the Spanish population. Diabet.es study. European Journal of Clinical Investigation, 2013, 43, 1-10.	1.7	16
1043	Statins for the primary prevention of cardiovascular disease. The Cochrane Library, 2021, 2021, CD004816.	1.5	933
1044	Emerging anti-inflammatory drugs for atherosclerosis. Expert Opinion on Emerging Drugs, 2013, 18, 193-205.	1.0	30
1045	Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes)., 2013, , 439-457.		0
1046	Visit-to-visit variability of blood pressure. Blood Pressure Monitoring, 2013, 18, 232-238.	0.4	21
1047	Dyslipidemia in Patients with Chronic and End-Stage Kidney Disease. CardioRenal Medicine, 2013, 3, 165-177.	0.7	26

#	ARTICLE	IF	CITATIONS
1048	Drugs for Elevated Low-Density Lipoprotein Cholesterol. , 2013, , 421-433.		0
1049	A review of statin use in patients with acute coronary syndrome in Western and Japanese populations. Journal of International Medical Research, 2013, 41, 523-536.	0.4	13
1050	Targeting Interleukin-1 in Heart Disease. Circulation, 2013, 128, 1910-1923.	1.6	253
1051	Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. Journal of Human Hypertension, 2013, 27, 13-17.	1.0	61
1052	Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. AIDS Research and Human Retroviruses, 2013, 29, 547-556.	0.5	34
1053	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013, 4, 325-339.	4.3	342
1054	Rosuvastatin prevents pressure overload-induced myocardial hypertrophy via inactivation of the Akt, ERK1/2 and GATA4 signaling pathways in rats. Molecular Medicine Reports, 2013, 8, 385-392.	1.1	15
1055	Radiographic Contrast-Media-Induced Acute Kidney Injury: Pathophysiology and Prophylactic Strategies. ISRN Radiology, 2013, 2013, 1-21.	1.2	26
1056	Emerging families of biomarkers for coronary artery disease: inflammatory mediators. Vascular Health and Risk Management, 2013, 9, 435.	1.0	42
1057	Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial. Current Medicinal Chemistry, 2013, 20, 1323-1331.	1.2	159
1058	Metabolic biomarkers for predicting cardiovascular disease. Vascular Health and Risk Management, 2013, 9, 37.	1.0	28
1059	Correlations Between the Level of High-Sensitivity C-Reactive Protein and Cardiovascular Risk Factors in Korean Adults with Cardiovascular Disease or Diabetes Mellitus: The CALLISTO Study. Journal of Atherosclerosis and Thrombosis, 2013, 20, 616-622.	0.9	23
1060	Increased C-reactive Protein Associates with Elevated Carotid Intima-Media Thickness in Chinese Adults with Normal Low Density Lipoprotein Cholesterol Levels. Journal of Atherosclerosis and Thrombosis, 2013, 20, 575-584.	0.9	8
1061	The Effect of Rosuvastatin on Inflammation, Matrix Turnover and Left Ventricular Remodeling in Dilated Cardiomyopathy: A Randomized, Controlled Trial. PLoS ONE, 2014, 9, e89732.	1.1	9
1062	Elevated C-Reactive Protein Levels and Enhanced High Frequency Vasomotion in Patients with Ischemic Heart Disease during Brachial Flow-Mediated Dilation. PLoS ONE, 2014, 9, e110013.	1.1	3
1063	Effect of clinical and RBC hemorheological parameters on myocardial perfusion in patients with type 2 diabetes mellitus. Biorheology, 2014, 51, 215-226.	1.2	5
1064	Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thrombosis and Haemostasis, 2014, 112, 224-242.	1.8	41
1065	High-Sensitivity C-Reactive Protein as a Predictor of Cardiovascular Events after ST-Elevation Myocardial Infarction. Arquivos Brasileiros De Cardiologia, 2014, 103, 69-75.	0.3	17

#	ARTICLE	IF	CITATIONS
1066	New frontiers in obstructive sleep apnoea. <i>Clinical Science</i> , 2014, 127, 209-216.	1.8	46
1067	Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort. <i>International Journal of Cancer</i> , 2014, 134, 1862-1870.	2.3	25
1068	Low serum level of high-sensitivity C-reactive protein in a Japanese patient with maturity-onset diabetes of the young type 3 (MODY3). <i>Journal of Diabetes Investigation</i> , 2014, 5, 513-516.	1.1	5
1069	Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials. <i>International Journal of Cardiology</i> , 2014, 177, 152-160.	0.8	7
1070	Statins use and the risk of acute kidney injury: a meta-analysis. <i>Renal Failure</i> , 2014, 36, 651-657.	0.8	8
1071	Critical Review of High-Sensitivity C-Reactive Protein and Coronary Artery Calcium for the Guidance of Statin Allocation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 315-322.	0.9	13
1073	C-Reactive Protein: Clinical and Epidemiological Perspectives. <i>Cardiology Research and Practice</i> , 2014, 2014, 1-10.	0.5	83
1074	Can statins prevent pregnancy complications?. <i>Journal of Reproductive Immunology</i> , 2014, 101-102, 161-167.	0.8	40
1075	Targeting Inflammation: Impact on Atherothrombosis. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 9-18.	1.1	12
1076	Screening Low-Risk Individuals for Coronary Artery Disease. <i>Current Atherosclerosis Reports</i> , 2014, 16, 402.	2.0	4
1077	The Guidelines Battle on Starting Statins. <i>New England Journal of Medicine</i> , 2014, 370, 1652-1658.	13.9	19
1078	Identification of Inflamed Atherosclerotic Lesions In Vivo Using PET-CT. <i>Inflammation</i> , 2014, 37, 426-434.	1.7	17
1079	A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: Effect on inflammation, psychopathology, cognition and lipid metabolism. <i>Schizophrenia Research</i> , 2014, 159, 395-403.	1.1	51
1080	Inflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target. <i>Current Atherosclerosis Reports</i> , 2014, 16, 435.	2.0	413
1081	Lipid pharmacotherapy for treatment of atherosclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1119-1125.	0.9	13
1082	HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells—New mechanistic insights of atherosclerosis. <i>BioFactors</i> , 2014, 40, 295-302.	2.6	27
1083	Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial. <i>Clinical Rheumatology</i> , 2014, 33, 1273-1278.	1.0	18
1084	Prospective Coronary Heart Disease Screening in Asymptomatic Hodgkin Lymphoma Patients Using Coronary Computed Tomography Angiography: Results and Risk Factor Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 59-66.	0.4	56

#	ARTICLE	IF	CITATIONS
1085	A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. <i>Atherosclerosis</i> , 2014, 236, 91-100.	0.4	106
1086	The role of statins in the prevention of contrast induced nephropathy: a meta-analysis of 8 randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 493-502.	1.0	21
1087	C-reactive protein levels in patients at cardiovascular risk: EURIKA study. <i>BMC Cardiovascular Disorders</i> , 2014, 14, 25.	0.7	40
1088	Association between C-reactive protein level and echocardiography assessed left ventricular function in first ST-segment elevation myocardial infarction patients who underwent primary coronary intervention. <i>Journal of Cardiology</i> , 2014, 63, 402-408.	0.8	4
1089	Long-term effects of birth weight and breastfeeding duration on inflammation in early adulthood. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2014, 281, 20133116.	1.2	48
1090	Pleiotropic Effects of Platelet P2Y ₁₂ Receptor Inhibitors: Fact or Fiction?. <i>Current Pharmaceutical Design</i> , 2014, 20, 4597-4604.	0.9	4
1091	Efficacy of Short-Term High-Dose Statin Pretreatment in Prevention of Contrast-Induced Acute Kidney Injury: Updated Study-Level Meta-Analysis of 13 Randomized Controlled Trials. <i>PLoS ONE</i> , 2014, 9, e111397.	1.1	24
1093	Protective effects of quercetin and taraxasterol against H ₂ O ₂ -induced human umbilical vein endothelial cell injury in vitro. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1253-1260.	0.8	46
1094	Predicting in-hospital mortality using routine parameters in unselected nonsurgical emergency department patients. <i>Notfall Und Rettungsmedizin</i> , 2015, 18, 501-509.	0.2	1
1095	Vascular and plaque imaging with ultrasmall superparamagnetic particles of iron oxide. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, 83.	1.6	40
1096	A novel anti-inflammatory natural product from <i>Sphaeranthus indicus</i> inhibits expression of VCAM1 and ICAM1, and slows atherosclerosis progression independent of lipid changes. <i>Nutrition and Metabolism</i> , 2015, 12, 20.	1.3	22
1097	Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease. <i>Pharmacotherapy</i> , 2015, 35, 771-779.	1.2	4
1098	The art of modeling adherence: shades or shapes?. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1114-1116.	0.9	1
1099	Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 970-981.	2.8	88
1100	Novel Inflammatory Markers in Hyperlipidemia: Clinical Implications. <i>Current Medicinal Chemistry</i> , 2015, 22, 2727-2743.	1.2	27
1101	Association of Lipid Abnormalities with High-Sensitivity C - reactive Protein in Patients Treated with Atorvastatin. <i>Journal of Diabetes & Metabolism</i> , 2015, 06, .	0.2	0
1102	The Effects of Statins on Infections after Stroke or Transient Ischemic Attack: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0130071.	1.1	6
1103	Pitavastatin Reduces Inflammation in Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice with Late Stage Renal Disease. <i>PLoS ONE</i> , 2015, 10, e0138047.	1.1	13

#	ARTICLE	IF	CITATIONS
1105	C-Reactive Protein As a Marker of Melanoma Progression. <i>Journal of Clinical Oncology</i> , 2015, 33, 1389-1396.	0.8	71
1106	Systemic Inflammation Associated With World Trade Center Dust Exposures and Airway Abnormalities in the Local Community. <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, 610-616.	0.9	28
1107	Cystatin C and long term risk of community-acquired sepsis: a population-based cohort study. <i>BMC Nephrology</i> , 2015, 16, 61.	0.8	11
1108	Red cell distribution width as a novel predictor for clinical outcomes in patients with paroxysmal atrial fibrillation. <i>Europace</i> , 2015, 17, ii83-ii88.	0.7	33
1109	Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease. , 2015, , 1-18.		2
1110	HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?. <i>Annals of Hematology</i> , 2015, 94, 1-12.	0.8	13
1111	Acute myocardial infarction in young Bangladeshis: A comparison with older patients. <i>Journal of Indian College of Cardiology</i> , 2015, 5, 20-24.	0.1	3
1112	Predictive impact on mediumterm mortality of hematological parameters in Acute Coronary Syndromes: added value on top of GRACE risk score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 172-179.	0.4	23
1113	Cardiovascular Biomarker Assessment Across Glycemic Status. , 2015, , 245-268.		1
1114	Rationale and design of the LosmApimod To Inhibit p38 MAP kinase as a TherapeUtic target and moDify outcomes after an acute coronary syndromE trial. <i>American Heart Journal</i> , 2015, 169, 622-630.e6.	1.2	31
1115	The Role of Statins in the Setting of HIV Infection. <i>Current HIV/AIDS Reports</i> , 2015, 12, 305-312.	1.1	29
1116	Efficacy of Locally Delivered 1.2% Rosuvastatin Gel To Nonâ€Surgical Treatment of Patients With Chronic Periodontitis: A Randomized, Placeboâ€Controlled Clinical Trial. <i>Journal of Periodontology</i> , 2015, 86, 738-745.	1.7	47
1117	Coronary Heart Disease Syndromes: Pathophysiology and Clinical Recognition. <i>Cardiovascular Medicine</i> , 2015, , 365-407.	0.0	5
1118	High-Sensitivity C-Reactive Protein and Statin Initiation. <i>Angiology</i> , 2015, 66, 503-507.	0.8	1
1119	Impact of systemic enzyme supplementation on low-grade inflammation in humans. <i>PharmaNutrition</i> , 2015, 3, 83-88.	0.8	4
1120	Mediators of the Effect of Body Mass Index on Coronary Heart Disease. <i>Epidemiology</i> , 2015, 26, 153-162.	1.2	39
1121	Statin Use and Risk of Sepsis After Percutaneous Nephrolithotomy. <i>Journal of Endourology</i> , 2015, 29, 1126-1130.	1.1	3
1123	Effect of Atorvastatin on Growth Differentiation Factor-15 in Patients with Type 2 Diabetes Mellitus and Dyslipidemia. <i>Diabetes and Metabolism Journal</i> , 2016, 40, 70.	1.8	6

#	ARTICLE	IF	CITATIONS
1124	Inflammation and thrombosis – testing the hypothesis with anti-inflammatory drug trials. <i>Thrombosis and Haemostasis</i> , 2016, 116, 1012-1021.	1.8	42
1125	High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities. <i>Clinics</i> , 2016, 71, 235-242.	0.6	78
1126	Association between hs-CRP Levels and the Outcomes of Patients with Small-Artery Occlusion. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 191.	1.7	15
1127	Multimorbidity in chronic disease: impact on health care resources and costs. <i>Risk Management and Healthcare Policy</i> , 2016, Volume 9, 143-156.	1.2	315
1128	Clinical relevance for lowering C-reactive protein with statins. <i>Annals of Medicine</i> , 2016, 48, 516-524.	1.5	23
1129	Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. <i>Scientific Reports</i> , 2016, 6, 23587.	1.6	29
1130	C-Reactive Protein: A Clinical Marker in Cardiovascular Disease. , 2016, , 143-165.		1
1131	Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 71-80.	1.6	98
1132	Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 201-219.	1.0	47
1133	The effect of statin treatment on the prevention of stent mediated flow limited edge dissections during PCI in patients with stable angina. <i>International Journal of Cardiology</i> , 2016, 220, 365-370.	0.8	0
1134	Platelet-Rich Fibrin With 1.2% Rosuvastatin for Treatment of Intraony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial. <i>Journal of Periodontology</i> , 2016, 87, 1468-1473.	1.7	32
1135	Red cell distribution width is increased in chronic thromboembolic pulmonary hypertension. <i>Clinical Respiratory Journal</i> , 2016, 10, 54-60.	0.6	16
1136	Effect of Statin Treatment and Low-Density Lipoprotein-Cholesterol on Short-Term Mortality in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention – A Multicenter Registry From Tokyo CCU Network Database –. <i>Circulation Journal</i> , 2016, 80, 461-468.	0.7	17
1137	Effects of 4 Statins on Regression of Coronary Plaque in Acute Coronary Syndrome. <i>Circulation Journal</i> , 2016, 80, 1634-1643.	0.7	19
1138	PCSK9 Inhibitors. <i>Journal of Pharmacy Technology</i> , 2016, 32, 201-209.	0.5	1
1139	Repurposing of approved cardiovascular drugs. <i>Journal of Translational Medicine</i> , 2016, 14, 269.	1.8	76
1140	Unmet needs in the management of atherosclerotic cardiovascular disease: Is there a role for emerging anti-inflammatory interventions?. <i>International Journal of Cardiology</i> , 2016, 221, 581-586.	0.8	12
1141	Statins for Prevention of Cardiovascular Disease in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2008.	3.8	459

#	ARTICLE	IF	CITATIONS
1143	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. American Journal of Hypertension, 2016, 29, 1117-1124.	1.0	13
1144	Chronic Statin Use and Long-Term Rates of Sepsis. Journal of Intensive Care Medicine, 2016, 31, 386-396.	1.3	9
1145	Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. European Heart Journal, 2016, 37, 1720-1722.	1.0	188
1146	From Lipids to Inflammation. Circulation Research, 2016, 118, 732-749.	2.0	180
1147	A Test in Context. Journal of the American College of Cardiology, 2016, 67, 712-723.	1.2	258
1148	Inflammatory cytokines in atherosclerosis: current therapeutic approaches. European Heart Journal, 2016, 37, 1723-1732.	1.0	346
1149	Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?. Current Atherosclerosis Reports, 2016, 18, 21.	2.0	207
1150	From C-Reactive Protein to Interleukin-6 to Interleukin-1. Circulation Research, 2016, 118, 145-156.	2.0	680
1151	Low-Density Lipoprotein Cholesterol Concentrations and Association of High-Sensitivity C-Reactive Protein Concentrations With Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology, 2016, 183, 46-52.	1.6	27
1152	AVC pÃ©riopÃ©ratoire. Canadian Journal of Anaesthesia, 2016, 63, 193-204.	0.7	91
1153	Rosuvastatin 1.2 mg In Situ Gel Combined With 1:1 Mixture of Autologous Platelet-Rich Fibrin and Porous Hydroxyapatite Bone Graft in Surgical Treatment of Mandibular Class II Furcation Defects: A Randomized Clinical Control Trial. Journal of Periodontology, 2016, 87, 5-13.	1.7	55
1155	Drug Effects and Clinical Investigations for Contrast-Induced Nephropathy After Coronary Angiography or Percutaneous Coronary Intervention in Patients With Diabetes. American Journal of Therapeutics, 2017, 24, e423-e430.	0.5	7
1156	Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study. Diabetes Therapy, 2017, 8, 309-319.	1.2	3
1157	Classification by Mechanisms of Cardiotoxicity. , 2017, , 13-34.		2
1158	Population Impact & Efficiency of Benefit-Targeted Versus Risk-Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease. Journal of the American Heart Association, 2017, 6, .	1.6	14
1159	American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 2017, 23, 1-87.	1.1	766
1160	Benefits of Statin Therapy in Patients With Acute Myocardial Infarction With Serum Low-Density Lipoprotein Cholesterol \geq 50 mg/dl. American Journal of Cardiology, 2017, 120, 174-180.	0.7	6
1161	Cardiovascular Risk Assessment. Medical Clinics of North America, 2017, 101, 673-688.	1.1	25

#	ARTICLE	IF	CITATIONS
1162	Emerging role of various signaling pathways in the pathogenesis and therapeutics of atherosclerosis. <i>Reviews in Vascular Medicine</i> , 2017, 10-11, 1-12.	0.4	9
1163	High-sensitivity C-reactive protein is an independent marker of abnormal coronary vasoreactivity in patients with non-obstructive coronary artery disease. <i>American Heart Journal</i> , 2017, 190, 1-11.	1.2	25
1164	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	2.7	105
1165	Do Statins Have Antidepressant Effects?. <i>CNS Drugs</i> , 2017, 31, 335-343.	2.7	22
1166	Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 1-26.	1.0	45
1167	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1119-1131.	13.9	6,227
1168	Red blood cell distribution width as a risk factor for in-hospital mortality in obstetric patients admitted to an intensive care unit: a single centre retrospective cohort study. <i>BMJ Open</i> , 2017, 7, e012849.	0.8	6
1169	Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy. <i>Medicine (United States)</i> , 2017, 96, e7384.	0.4	35
1170	The renoprotective effects of simvastatin and atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Medicine (United States)</i> , 2017, 96, e7351.	0.4	7
1171	An Aggregate Biomarker Risk Score Predicts High Risk of Near-Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes). <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
1172	Pleiotropic effects of statins on acute kidney injury: involvement of KrÄ¼ppel-like factor 4. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 175-181.	0.7	9
1173	Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2017, 69, 69-77.	2.1	76
1174	The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1260.	1.8	28
1175	Simvastatin reduces adrenal catecholamine secretion evoked by stimulation of cholinergic nicotinic and angiotensinergic AT1 receptors. <i>Archives of Pharmacal Research</i> , 2018, 41, 333-346.	2.7	1
1176	Microcirculation and biomarkers in patients with resistant or mild-to-moderate hypertension: a cross-sectional study. <i>Hypertension Research</i> , 2018, 41, 515-523.	1.5	25
1177	Gemcabene, a first-in-class lipid-lowering agent in late-stage development, down-regulates acute-phase C-reactive protein via C/EBP-Î-mediated transcriptional mechanism. <i>Molecular and Cellular Biochemistry</i> , 2018, 449, 167-183.	1.4	15
1178	Inflammation and Cardiovascular Disease Risk: A Case Study of HIV and Inflammatory Joint Disease. <i>American Journal of Medicine</i> , 2018, 131, 442.e1-442.e8.	0.6	4
1179	Evaluation of endothelial function by VOP and inflammatory biomarkers in patients with arterial hypertension. <i>Journal of Human Hypertension</i> , 2018, 32, 105-113.	1.0	2

#	ARTICLE	IF	CITATIONS
1180	Canakinumab for Atherosclerotic Disease. <i>New England Journal of Medicine</i> , 2018, 378, 196-200.	13.9	13
1181	Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy. <i>Circulation</i> , 2018, 138, 141-149.	1.6	151
1182	Will Reducing Inflammation Reduce Vascular Event Rates?. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 317-319.	2.3	11
1183	Effect of vitamin D supplementation on reduction of cardiometabolic risk in patients with type 2 diabetes mellitus and dyslipidemia. <i>International Journal of Diabetes in Developing Countries</i> , 2018, 38, 221-227.	0.3	5
1184	Effects of Anti-Inflammatory Medications in Patients With Coronary Artery Disease: A Focus on Losmapimod. <i>Cardiology in Review</i> , 2018, 26, 152-156.	0.6	7
1185	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 319-328.	6.3	628
1186	The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. <i>Food and Function</i> , 2018, 9, 6116-6128.	2.1	32
1187	A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity. <i>Chinese Medical Journal</i> , 2018, 131, 508-515.	0.9	10
1188	Diet-Modulated Lipoprotein Metabolism and Vascular Inflammation Evaluated by 18F-fluorodeoxyglucose Positron Emission Tomography. <i>Nutrients</i> , 2018, 10, 1382.	1.7	1
1189	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. <i>European Heart Journal</i> , 2018, 39, 4109-4111.	1.0	44
1190	Clinician's Guide to Reducing Inflammation to Reduce Atherothrombotic Risk. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3320-3331.	1.2	120
1191	Targeted HFpEF therapy based on matchmaking of human and animal models. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2018, 315, H1670-H1683.	1.5	16
1192	Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer. <i>Journal of Stroke</i> , 2018, 20, 71-79.	1.4	28
1193	Evidence-based nutritional and pharmacological interventions targeting chronic low-grade inflammation in middle-age and older adults: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2018, 46, 42-59.	5.0	111
1194	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 948-955.	0.8	46
1195	Wide-range CRP versus high-sensitivity CRP on Roche analyzers: focus on low-grade inflammation ranges and high-sensitivity cardiac troponin T levels. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 346-351.	0.6	9
1196	Anti-Inflammatory Treatment. , 2018, , 237-271.		0
1197	The Role of Nutraceuticals in Statin-Intolerant Patients. <i>Journal of the American College of Cardiology</i> , 2018, 72, 96-118.	1.2	216

#	ARTICLE	IF	CITATIONS
1198	Replication and reproducibility issues in the relationship between C-reactive protein and depression: A systematic review and focused meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 85-114.	2.0	99
1199	A hook effect-free immunochromatographic assay (HEF-ICA) for measuring the C-reactive protein concentration in one drop of human serum. <i>Theranostics</i> , 2018, 8, 3189-3197.	4.6	31
1200	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. <i>Annals of Medicine</i> , 2018, 50, 461-484.	1.5	28
1201	The effect of group-based cognitive behavioral therapy on inflammatory biomarkers in patients with coronary heart disease—results from the SUPRIM-trial. <i>Upsala Journal of Medical Sciences</i> , 2018, 123, 167-173.	0.4	1
1202	Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019, 8, e012428.	1.6	10
1203	Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia. <i>Hypertension Research</i> , 2019, 42, 1923-1931.	1.5	7
1204	Functionality of C-Reactive Protein for Atheroprotection. <i>Frontiers in Immunology</i> , 2019, 10, 1655.	2.2	20
1205	Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 201.	0.7	8
1206	Atherosclerosis Pathogenesis and Microvascular Dysfunction. , 2019, , .		8
1207	2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. <i>Atherosclerosis</i> , 2019, 290, 140-205.	0.4	1,753
1208	Atherosclerosis risk assessment in patients with chronic obstructive pulmonary disease: a case-control study. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 1061-1071.	0.9	4
1209	Regulatory T cells: Possible mediators for the anti-inflammatory action of statins. <i>Pharmacological Research</i> , 2019, 149, 104469.	3.1	32
1210	Dual-modality imaging of atherosclerotic plaques using ultrasmall superparamagnetic iron oxide labeled with rhodamine. <i>Nanomedicine</i> , 2019, 14, 1935-1944.	1.7	6
1211	Anticytokine Agents. <i>Circulation Research</i> , 2019, 124, 437-450.	2.0	188
1212	C-Reactive Protein and Chronic Inflammation—Is It a Novel Therapeutic Target for Subsequent Cancer Death in Patients With Coronary Artery Disease?. <i>Circulation Journal</i> , 2019, 83, 513-514.	0.7	0
1213	Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses. <i>Scientific Reports</i> , 2019, 9, 8951.	1.6	18
1214	Intraluminal Delivery of Simvastatin Attenuates Intimal Hyperplasia After Arterial Injury. <i>Vascular and Endovascular Surgery</i> , 2019, 53, 379-386.	0.3	9
1215	Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. <i>Immunity</i> , 2019, 50, 778-795.	6.6	639

#	ARTICLE	IF	CITATIONS
1216	Compensated Interferometry Measures of CYFRA 21â€™1 Improve Diagnosis of Lung Cancer. ACS Combinatorial Science, 2019, 21, 465-472.	3.8	26
1217	Statins: Rationale, Mode of Action, and Side Effects. , 2019, , 171-200.		6
1218	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome. JAMA Cardiology, 2019, 4, 314.	3.0	79
1219	Efficacy of antiâ€™inflammatory treatment on major depressive disorder or depressive symptoms: metaâ€™analysis of clinical trials. Acta Psychiatrica Scandinavica, 2019, 139, 404-419.	2.2	257
1220	Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 16.	1.1	109
1222	â€™Precision medicineâ€™™ and ischaemic heart disease: the stage is set for the new antibody based therapies (lipid lowering and anti-inflammatory). European Heart Journal Supplements, 2019, 21, B73-B75.	0.0	1
1223	NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. International Journal of Molecular Sciences, 2019, 20, 1599.	1.8	138
1224	A Control-Theoretic Model of Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 785.	1.8	12
1225	Cardiovascular disease in the QUEST-RA study, 10â€™%years later. Arthritis Research and Therapy, 2019, 21, 242.	1.6	3
1228	Roles of Achieved Levels of Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein on Cardiovascular Outcome in Statin Therapy. Cardiovascular Therapeutics, 2019, 2019, 1-10.	1.1	4
1229	Baseline Red Blood Cell Distribution Width as a Predictor of Stroke Occurrence and Outcome: A Comprehensive Meta-Analysis of 31 Studies. Frontiers in Neurology, 2019, 10, 1237.	1.1	48
1231	The effects of statin use on inflammatory markers among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 2019, 141, 85-103.	3.1	31
1232	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115, 10-19.	1.8	72
1233	Effect of cinnamon (Cinnamomum Zeylanicum) supplementation on serum C-reactive protein concentrations: A meta-analysis and systematic review. Complementary Therapies in Medicine, 2019, 42, 271-278.	1.3	18
1234	Inflammatory Markers and Novel Risk Factors. Contemporary Cardiology, 2019, , 87-98.	0.0	0
1235	The Effects of Known Cardioprotective Drugs on Proinflammatory Cytokine Secretion From Human Coronary Artery Endothelial Cells. American Journal of Therapeutics, 2019, 26, e321-e332.	0.5	20
1236	The intestinal microbiota fuelling metabolic inflammation. Nature Reviews Immunology, 2020, 20, 40-54.	10.6	573
1237	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871

#	ARTICLE	IF	CITATIONS
1238	A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1505-1513.	0.9	3
1239	Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial. <i>Journal of Cardiology</i> , 2020, 75, 500-506.	0.8	4
1240	Reduction in hsCRP levels is associated with decreased incidence of cardiovascular events in Japanese hypertensive women but not in men. <i>Scientific Reports</i> , 2020, 10, 17040.	1.6	7
1241	Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3689.	1.0	3
1242	Nocturnal Continuous Positive Airway Pressure (nCPAP) Decreases High-Sensitivity C-Reactive Protein (hs-CRP) in Obstructive Sleep Apnea-Hypopnea Syndrome. <i>Sleep Disorders</i> , 2020, 2020, 1-10.	0.8	5
1243	Inflammation and cardiovascular disease: From mechanisms to therapeutics. <i>American Journal of Preventive Cardiology</i> , 2020, 4, 100130.	1.3	142
1244	Inflammation of carotid plaques and risk of cerebrovascular events. <i>Annals of Translational Medicine</i> , 2020, 8, 1281-1281.	0.7	18
1245	Targeting Inflammation After Myocardial Infarction. <i>Current Cardiology Reports</i> , 2020, 22, 110.	1.3	19
1246	Cholesterol metabolism and brain injury in neonatal encephalopathy. <i>Pediatric Research</i> , 2021, 90, 37-44.	1.1	8
1247	Inflammation in Coronary Atherosclerosis and Its Therapeutic Implications. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 347-362.	1.3	23
1248	Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 361-379.	3.5	119
1249	Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment. <i>Heart Failure Reviews</i> , 2021, 26, 1159-1173.	1.7	57
1250	Effects of chromium supplementation on inflammatory biomarkers: A systematic review and dose-response meta-analysis of randomized controlled trials. <i>European Journal of Integrative Medicine</i> , 2020, 37, 101147.	0.8	5
1251	Changes in C-reactive protein in response to anti-inflammatory therapy as a predictor of cardiovascular outcomes: A systematic review and meta-analysis. <i>JRSM Cardiovascular Disease</i> , 2020, 9, 204800402092923.	0.4	4
1252	Statins: Could an old friend help in the fight against COVID-19?. <i>British Journal of Pharmacology</i> , 2020, 177, 4873-4886.	2.7	101
1253	Statins in the treatment of depression: Hype or hope?. , 2020, 215, 107625.		26
1254	An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 531-539.	0.9	17
1255	High-sensitivity C-reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. <i>Journal of the American Heart Association</i> , 2020, 9, e013600.	1.6	43

#	ARTICLE	IF	CITATIONS
1256	Lowering inflammation through lipid-lowering therapy: are we there yet?. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 93-94.	1.8	1
1257	Prediction and early detection of cardiovascular disease in South Asians with diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 385-393.	1.8	5
1258	Sex as a Biological Variable in Atherosclerosis. Circulation Research, 2020, 126, 1297-1319.	2.0	190
1259	Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. Journal of Clinical Medicine, 2020, 9, 1033.	1.0	4
1260	Combating Inflammation in Cardiovascular Disease. Heart Lung and Circulation, 2021, 30, 197-206.	0.2	39
1261	Optical Coherence Tomography Predictors for a Favorable Vascular Response to Statin Therapy. Journal of the American Heart Association, 2021, 10, e018205.	1.6	5
1262	Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes. Frontiers in Cardiovascular Medicine, 2020, 7, 631398.	1.1	14
1263	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. Current Pharmaceutical Design, 2021, 27, 263-275.	0.9	27
1264	Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection. Nature Reviews Nephrology, 2021, 17, 335-349.	4.1	140
1265	The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. Journal of Personalized Medicine, 2021, 11, 103.	1.1	16
1266	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. Wiener Klinische Wochenschrift, 2021, 133, 958-965.	1.0	7
1267	Automatic text-mining as an unbiased approach to uncover molecular associations between periodontitis and coronary artery disease. Biomarkers, 2021, 26, 385-394.	0.9	7
1269	Potential Impact of Statins on Neuronal Stress Responses in Patients at Risk for Cardiovascular Disease. Journal of Personalized Medicine, 2021, 11, 261.	1.1	2
1271	Coronary heart disease risk: Low-density lipoprotein and beyond. Trends in Cardiovascular Medicine, 2022, 32, 181-194.	2.3	56
1272	Inflammation and Cardiovascular Disease: The Future. European Cardiology Review, 2021, 16, e20.	0.7	48
1273	Heterogeneous subpopulations of adventitial progenitor cells regulate vascular homeostasis and pathological vascular remodelling. Cardiovascular Research, 2022, 118, 1452-1465.	1.8	18
1274	Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis. Thrombosis Journal, 2021, 19, 32.	0.9	49
1275	Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis. Clínica E Investigaci3n En Arteriosclerosis (English Edition), 2021, 33, 117-126.	0.1	1

#	ARTICLE	IF	CITATIONS
1276	Triglycerides and Residual Atherosclerotic Risk. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3031-3041.	1.2	82
1277	Plausible Positive Effects of Statins in COVID-19 Patient. <i>Cardiovascular Toxicology</i> , 2021, 21, 781-789.	1.1	6
1278	The Role of C-reactive Protein in Patient Risk Stratification and Treatment. <i>European Cardiology Review</i> , 2021, 16, e28.	0.7	7
1279	The Effect of Statins on C-Reactive Protein in Stroke Patients: A Systematic Review of Clinical Trials. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	1.4	5
1280	Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1175-1186.	1.3	7
1281	Oxidative Stress-Induced Ferroptosis in Cardiovascular Diseases and Epigenetic Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 685775.	1.8	9
1282	Inflammation, Cholesterol, and Stroke Risk: Building Evidence for a Dual Target Strategy for Secondary Prevention. <i>Stroke</i> , 2021, 52, 2837-2838.	1.0	1
1283	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. <i>Life</i> , 2021, 11, 105.	1.1	22
1284	The Arterial Inflammation Hypothesis. <i>Archives of Internal Medicine</i> , 2002, 162, 2249-a-2251.	4.3	2
1285	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0, , 397-425.		2
1287	Statins in Critical Illness. , 2005, , 477-487.		2
1288	Protection of Endothelial Function. <i>Handbook of Experimental Pharmacology</i> , 2005, , 619-644.	0.9	14
1289	Inflammation Is a Crucial Feature of Atherosclerosis and a Potential Target to Reduce Cardiovascular Events. <i>Handbook of Experimental Pharmacology</i> , 2005, , 697-722.	0.9	11
1290	Dyslipidemias. , 2003, , 1019-1029.		1
1291	Inflammation, C-Reactive Protein, and Vulnerable Plaques. , 2007, , 611-620.		2
1294	The Metabolic Syndrome. , 2010, , 822-839.		2
1295	Lipids, Lipoproteins, Apolipoproteins, and Other Cardiovascular Risk Factors. , 2012, , 731-805.		29
1296	Clinical approach to the inflammatory etiology of cardiovascular diseases. <i>Pharmacological Research</i> , 2020, 159, 104916.	3.1	56

#	ARTICLE	IF	CITATIONS
1297	Markers of preclinical atherosclerosis and their clinical relevance. <i>Vasa - European Journal of Vascular Medicine</i> , 2015, 44, 247-256.	0.6	28
1300	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	3.1	174
1302	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	3.9	327
1303	Isoprenoids as mediators of the biological effects of statins. <i>Journal of Clinical Investigation</i> , 2002, 110, 285-288.	3.9	210
1304	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003, 111, 1805-1812.	3.9	1,673
1305	C-reactive protein: a critical update. <i>Journal of Clinical Investigation</i> , 2003, 111, 1805-1812.	3.9	2,941
1306	CMR plaque characterization. , 2005, , 116-127.		2
1307	High-Sensitivity C-Reactive Protein and Risk of Sepsis. <i>PLoS ONE</i> , 2013, 8, e69232.	1.1	38
1308	C-reactive protein and coronary heart disease - risk marker or risk factor?. <i>The Journal of Clinical and Scientific Research</i> , 2012, , 178-186.	0.1	1
1310	Congestive Heart Failure in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1084-1090.	3.0	241
1311	Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. , 2010, , .		28
1312	Statins in the treatment of chronic heart failure: Beyond the hypolipidemic effects. <i>Arterial Hypertension (Russian Federation)</i> , 2012, 18, 11-17.	0.1	1
1313	Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease. <i>Vascular Health and Risk Management</i> , 2006, 2, 221-237.	1.0	75
1314	Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events. <i>BioDrugs</i> , 2012, 26, 217-233.	2.2	2
1315	The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview. <i>Current Vascular Pharmacology</i> , 2008, 6, 258-270.	0.8	49
1316	Simvastatin Induces Apoptosis of Fibroblast-Like Synoviocytes~!2009-02-16~!2009-03-24~!2009-09-07~!. <i>Open Rheumatology Journal</i> , 2009, 3, 35-40.	0.1	7
1317	Induction of TGF- β 1 and BMP-2 by Simvastatin in Human Periodontal Ligament Cells. <i>Journal of Japanese Society of Periodontology</i> , 2005, 47, 168-177.	0.1	1
1318	The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 66-70.	0.6	1

#	ARTICLE	IF	CITATIONS
1319	The implication of proinflammatory cytokines in type 2 diabetes. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 5187.	3.0	74
1322	The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. <i>International Journal of Biological Chemistry</i> , 2008, 3, 30-34.	0.3	5
1323	Investigation of the Effects of Statin Therapy on Serum Vitamin E Status in Patients with Dyslipidemia. <i>Pakistan Journal of Nutrition</i> , 2008, 7, 561-565.	0.2	1
1324	JUPITER to Earth: A statin helps people with normal LDL-C and high hs-CRP, but what does it mean?. <i>Cleveland Clinic Journal of Medicine</i> , 2009, 76, 37-44.	0.6	17
1325	Novel Markers in the Acute Coronary Syndrome: BNP, IL-6, PAPP-A. <i>American Journal of Critical Care</i> , 2002, 11, 168-172.	0.8	17
1326	High-Sensitivity C-Reactive Protein Is the Most Effective Prognostic Measurement of Acute Coronary Events. <i>American Journal of Critical Care</i> , 2002, 11, 482-486.	0.8	25
1327	Effect of preoperative statin therapy on myocardial protection and morbidity endpoints following off-pump coronary bypass surgery in patients with elevated C-reactive protein level. <i>Korean Journal of Anesthesiology</i> , 2010, 58, 136.	0.9	8
1328	Comparison of anti-inflammatory effect of atorvastatin with rosuvastatin in patients of acute coronary syndrome. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2015, 6, 130-135.	0.2	42
1329	Predictive Value of Circulating Vascular Endothelial Growth Factor-1 in Arterial Hypertension Patients. <i>Internal Medicine: Open Access</i> , 2013, s11, .	0.0	1
1330	The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. <i>EuroIntervention</i> , 2016, 12, e1366-e1374.	1.4	48
1331	Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study. <i>Anatolian Journal of Cardiology</i> , 2012, 12, 90-6.	0.4	6
1332	Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia. <i>Journal of Atherosclerosis and Thrombosis</i> , 2010, 17, 37-44.	0.9	34
1333	An Anti-Inflammatory Approach in the Therapeutic Choices for the Prevention of Atherosclerotic Events. , 0, , .		1
1334	Changes of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Research in Cardiovascular Medicine</i> , 2015, 5, e28997.	0.2	9
1335	Assessment of serum leptin, pregnancy-associated plasma protein A and CRP levels as indicators of plaque vulnerability in patients with acute coronary syndrome. <i>Cardiovascular Journal of Africa</i> , 2012, 23, 330-335.	0.2	12
1336	Hypercoagulation Testing in Ischemic Stroke. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 890-901.	1.2	43
1337	Repeated In-Stent Restenosis Despite Aggressive Lipid Lowering by PCSK-9 Inhibitor Treatment: A Case Report. <i>Tohoku Journal of Experimental Medicine</i> , 2021, 255, 123-126.	0.5	4
1338	HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003820.	3.9	29

#	ARTICLE	IF	CITATIONS
1339	Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall. , 2002, , 81-98.		1
1340	Cellular effects of HMG-CoA reductase inhibitors on blood cells (monocytes, macrophages, platelets). , 2002, , 55-80.		0
1341	Estado inflamatorio en el angor inestable e infarto de miocardio sin elevaci3n del segmento ST: Valor de la prote3na C-reactiva ultrasensible. Anales De Medicina Interna, 2002, 19, .	0.1	3
1342	Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromese. , 2003, , 427-438.		0
1343	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. , 2003, , 45-50.		10
1344	Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes. , 2003, , 291-303.		1
1345	A biomarker of inflammation in cardiovascular disease. , 2003, , 9-20.		0
1346	C-Reactive Protein for Primary Risk Assessment. , 2003, , 279-290.		0
1348	Unanswered questions about the use of statins. , 2003, , 228-240.		0
1349	Guidelines for clinical use of the statins. , 2003, , 200-212.		0
1350	Nutrition and IGF Proteins in Chronic Malnutrition and Critical Illness. , 2004, , 53-74.		0
1351	Serum Biomarkers in Prediction of Stroke Risk and Outcome. , 2004, , 257-278.		0
1352	Gender and Its Impact on Risk Factors for Cardiovascular Disease. , 2004, , 193-214.		2
1353	Herz, Gef3Ùe, Lunge. , 2004, , 81-196.		0
1354	B-Type Natriuretic Peptides in Acute Coronary Syndromes. , 2004, , 323-338.		0
1356	Determination of high sensitivity C-reactive protein: Clinical and analytical quality. Journal of Medical Biochemistry, 2005, 24, 85-93.	0.1	2
1357	Peritoneal Dialysis Prescription and Adequacy. , 2005, , 553-568.		1
1358	Vascular Inflammation as a Cardiovascular Risk Factor. , 2005, , 577-604.		0

#	ARTICLE	IF	CITATIONS
1359	Chronic infection and circulating markers of inflammation. , 2005, , 448-465.		0
1360	Obesity, Cytokines, and Other Inflammatory Markers. Nutrition and Disease Prevention, 2005, , 317-327.	0.1	1
1361	Inflammation in Cardiovascular Disease. , 2006, , 207-221.		1
1362	Neue, experimentelle und zukünftige Therapieansätze. , 2006, , 303-315.		0
1363	Analytic Issues for Clinical Use of C-Reactive Protein. , 2006, , 223-235.		0
1364	Lower Extremity Arterial Reconstruction in Patients With Diabetes Mellitus. , 2006, , 473-492.		1
1365	Women and Coronary Heart Disease. Fundamental and Clinical Cardiology, 2006, , 689-720.	0.0	0
1366	Inflammatory Mediators and C-Reactive Protein. Fundamental and Clinical Cardiology, 2006, , 441-462.	0.0	0
1368	Atherosclerosis and lipoprotein metabolism. , 2007, , 321-330.		6
1369	Atherosclerosis: Pathogenesis, Morphology, and Risk Factors. , 2007, , 1593-1613.		2
1371	Drugs for Elevated LDL-Cholesterol. , 2007, , 528-539.		0
1372	COPD as a systemic disease. Pulmonologiya, 2007, , 104-116.	0.2	2
1373	Biomarkers. , 2007, , 141-152.		0
1374	Modulation of Biomarkers of Inflammation. , 2009, , 396-409.		1
1375	NHG-Standaard Cardiovasculair risicomanagement. , 2009, , 106-152.		4
1376	Efectos no hipolipemiantes de las estatinas. Acta Medica Costarricense, 2008, 49, .	0.1	1
1377	Treatment of dyslipidemia in primary prevention and rosuvastatin. Turk Kardiyoloji Dernegi Arsivi, 2009, 39, 14-18.	0.6	0
1378	Peritoneal Dialysis Prescription and Adequacy. , 2010, , 432-445.		0

#	ARTICLE	IF	CITATIONS
1379	Inflammatory Markers and Novel Risk Factors. , 2011, , 107-123.		0
1380	Advanced Lipid Testing. , 2011, , 77-103.		0
1381	Collagen Vascular and Infectious Diseases. , 2011, , 687-702.		0
1383	Inflammatory Biomarkers. , 2012, , 481-495.		0
1384	Meta-analysis on the Role of High-sensitivity C-reactive Protein Monitoring in Relation to the Presence of Glucose Intolerance in Patients Treated with HMG-CoA Reductase Inhibitors. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2012, 38, 479-490.	0.0	0
1388	C-Reactive Protein Is Not Correlated With Endothelial Dysfunction in Overweight and Obese Women. Journal of Clinical Medicine Research, 2013, 5, 294-9.	0.6	4
1389	Prophylactic Statin Administration May Prevent Shortening of the Fibrillation Cycle Length in Patients With New-Onset Atrial Fibrillation. International Heart Journal, 2013, 54, 371-376.	0.5	2
1390	3-HMG-CoA Reductase Inhibitors and Inflammation: Underlying Mechanisms and Role in Atherosclerosis. Biosciences, Biotechnology Research Asia, 2013, 10, 683-689.	0.2	0
1391	Predictive Value of Circulating Vascular Endothelial Growth Factor-1 Level Measured Repeatedly During Long-Term Follow-Up in Patients with Arterial Hypertension after Acute Ischemic Stroke. Angiology: Open Access, 2014, 02, .	0.1	0
1392	Integration of Biomarkers with Plaque Imaging. Contemporary Cardiology, 2014, , 203-214.	0.0	0
1394	Circulating Vascular Endothelial Growth Factor-1 in Cardiovascular Disease. , 2016, , 341-357.		0
1395	A Critical Evaluation of the Role of Routine Uses of Statin as a Tool for Primary Prevention of Cardiovascular Diseases. Open Journal of Preventive Medicine, 2016, 06, 133-142.	0.2	0
1396	The Effects of Antiplatelet, Antithrombotic, and Thrombolytic Agents on Inflammation and Circulating Inflammatory Biomarkers. , 2016, , 89-120.		0
1397	The Relationship between High Sensitive C-reaction Protein (hs-CRP) and Diastolic Heart Function in Diabetes Mellitus Type II. Asian Journal of Pharmaceutical Research and Health Care, 2016, 8, 12.	0.0	0
1398	Recent advances in the pharmacotherapy of cardiovascular diseases. Intervencni A Akutni Kardiologie, 2018, 17, 108-112.	0.0	0
1399	1.2% rosuvastatin gel as a local drug delivery agent in smokers with chronic periodontitis â€œ A randomized controlled clinical trial. Journal of Advanced Clinical and Research Insights, 2019, 6, 110-115.	0.1	2
1400	Risk Factors and Prevention in Light of Atherosclerosis Being a Microvascular Disease. , 2019, , 75-95.		0
1402	Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?. Obesity and Metabolism, 2019, 16, 12-19.	0.4	0

#	ARTICLE	IF	CITATIONS
1403	C-reactive protein and cardiovascular disease: From animal studies to the clinic (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1211-1219.	0.8	32
1404	Effect of Bempedoic Acid on atherogenic lipids and inflammation: A meta-analysis. <i>Clínica E Investigaci3n En Arteriosclerosis</i> , 2020, 33, 117-126.	0.4	4
1405	C-Reactive Protein and Other Inflammatory Markers in Cardiovascular Disease: Inflammatory Disorders and Atherosclerosis. <i>Contemporary Cardiology</i> , 2021, , 565-583.	0.0	1
1406	Inflammation and Atherosclerotic Cardiovascular Disease. <i>Contemporary Cardiology</i> , 2021, , 289-333.	0.0	0
1407	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. <i>Current Vascular Pharmacology</i> , 2020, 19, 323-342.	0.8	15
1410	Lipide. , 2005, , 362-377.		0
1411	Ischemic Heart Disease in the Older Hypertensive Patient. , 2005, , 229-254.		0
1412	Unstable Angina and Non-ST Segment Elevation Myocardial Infarction (Acute Coronary Syndromes). , 2005, , 471-487.		0
1413	Controversies in Evaluation and Management of Lipid Disorders in Diabetes. , 2008, , 291-315.		0
1414	The impact of statins on the course of a new coronavirus infection: myth or reality?. <i>Å¾urno-Rossijskij Å¾urnal TerapevtiÅšskoj Praktiki</i> , 2020, 1, 102-108.	0.1	1
1415	Effect of cardiac rehabilitation on inflammation: A systematic review and meta-analysis of controlled clinical trials. <i>ARYA Atherosclerosis</i> , 2018, 14, 85-94.	0.4	6
1416	The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. <i>Transactions of the American Clinical and Climatological Association</i> , 2004, 115, 149-59; discussion159-60.	0.9	30
1417	Role of plaque inflammation in acute and recurrent coronary syndromes. <i>Netherlands Heart Journal</i> , 2004, 12, 106-109.	0.3	8
1418	Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins. <i>Journal of the National Medical Association</i> , 2005, 97, 1600-7.	0.6	10
1419	Biomarkers and Bioassays for Cardiovascular Diseases: Present and Future. <i>Biomarker Insights</i> , 2008, 3, 293-302.	1.0	1
1420	American heart association 2008 scientific sessions United European gastroenterology week american college of rheumatology scientific meeting. P and T, 2009, 34, 30-7.	1.0	0
1422	PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin. <i>Texas Heart Institute Journal</i> , 2009, 36, 530-9.	0.1	9
1423	Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL?. <i>Transactions of the American Clinical and Climatological Association</i> , 2011, 122, 256-89.	0.9	35

#	ARTICLE	IF	CITATIONS
1424	Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?. Transactions of the American Clinical and Climatological Association, 2013, 124, 174-90.	0.9	60
1425	C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian Journal of Internal Medicine, 2013, 4, 611-6.	0.1	30
1426	Overview of omega-3 Fatty Acid therapies. P and T, 2013, 38, 681-91.	1.0	72
1427	Positron emission tomography imaging for vascular inflammation evaluation in elderly subjects with different risk factors for cardiovascular diseases. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 283-92.	1.0	3
1428	Statins for everyone?. Heart Asia, 2010, 2, 80-1.	1.1	0
1429	Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. American Journal of Translational Research (discontinued), 2016, 8, 2862-75.	0.0	17
1430	Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 815-826.	1.1	4
1431	Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 220.	2.7	59
1432	Combined impact of residual inflammatory risk and chronic kidney disease on long-term clinical outcomes in patients undergoing percutaneous coronary intervention. Journal of Cardiology, 2021, , .	0.8	1
1433	Statins and Inflammation. Current Atherosclerosis Reports, 2021, 23, 80.	2.0	34
1434	A Review: Protein Identification by LC-MS: Principles, Instrumentation, and Applications. Iraqi Journal of Science, 0, , 2448-2466.	0.3	1
1435	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Molecular and Cellular Biochemistry, 2003, 246, 45-50.	1.4	12
1436	Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. Current Atherosclerosis Reports, 2006, 8, 7-8.	2.0	0
1437	Impact of 719Trp>Arg Polymorphism of KIF 6 Gene on Contrast Induced Nephropathy in Patients Undergoing Coronary Angiography or Percutaneous Coronary Intervention. Global Heart, 2022, 17, 16.	0.9	1
1438	Hemoglobin-to-Red-Cell Distribution Width Ratio Is a Novel Predictor of Long-Term Patient Outcomes After Percutaneous Coronary Intervention: A Retrospective Cohort Study. Frontiers in Cardiovascular Medicine, 2022, 9, 726025.	1.1	13
1439	Antioxidant Effects of Statins by Modulating Nrf2 and Nrf2/HO-1 Signaling in Different Diseases. Journal of Clinical Medicine, 2022, 11, 1313.	1.0	40
1441	A Dietitian-Led Vegan Program May Improve GlycA, and Other Novel and Traditional Cardiometabolic Risk Factors in Patients With Dyslipidemia: A Pilot Study. Frontiers in Nutrition, 2022, 9, 807810.	1.6	3
1442	Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. American Journal of Preventive Cardiology, 2022, 10, 100335.	1.3	58

#	ARTICLE	IF	CITATIONS
1443	Effect of <i>Trichilia monadelpha</i> (Thonn.) J. J. de Wilde (Meliaceae) extracts on C-reactive proteins levels and acute inflammation. <i>Scientific African</i> , 2022, 16, e01119.	0.7	0
1444	Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromese: Focus on <i>Chlamydia pneumoniae</i> . , 0, , 427-438.		0
1445	Gender, Hyperlipidemia, and Coronary Artery Disease. <i>Comprehensive Therapy</i> , 2003, 29, 07-17.	0.2	0
1447	New Developments in Treatment of Vulnerable Plaques. , 0, , 303-320.		0
1448	Emerging Approaches in Cardiovascular Prevention. , 0, , 219-230.		0
1449	Other Medical Therapies. , 0, , 330-347.		2
1450	Novel biomedical risk markers for cardiovascular disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, 41-55.	1.5	4
1452	Combined Effects of A Body Shape Index and Serum C-reactive Protein on Ischemic Stroke Incidence among Mongolians in China. <i>Biomedical and Environmental Sciences</i> , 2019, 32, 169-176.	0.2	3
1453	Acute Myocardial Infarction (AMI) as the Effect Modifiers to Modify the Association Between Red Blood Cell Distribution Width (RDW) and Mortality in Critically Ill Patients With Stroke. <i>Frontiers in Medicine</i> , 2022, 9, 754979.	1.2	0
1454	Treatment and Outcome of Castleman Disease: A Retrospective Report of 31 Patients. <i>Therapeutics and Clinical Risk Management</i> , 2022, Volume 18, 499-509.	0.9	2
1458	Concurrent exercise and aerobic-resistance exercise ameliorate the serum of Retinol-Binding Protein-4 level and insulin resistance in postmenopausal women. <i>Science and Sports</i> , 2022, , .	0.2	0
1459	Colchicine for Coronary Artery Disease: A Review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1460	The role of inflammation and the possibilities of inflammation reduction to prevent cardiovascular events. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	9
1461	WBC Count and the Risk of Cancer Mortality in a National Sample of U.S. Adults: Results from the Second National Health and Nutrition Examination Survey Mortality Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1052-1056.	1.1	84
1462	The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
1463	The Prediction of Cardiac Events Using Contemporary Risk Prediction Models after Radiation Therapy for Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3651.	1.7	1
1464	Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease. <i>American Journal of Cardiology</i> , 2022, 181, 1-8.	0.7	4
1465	Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases. <i>Foods</i> , 2022, 11, 2575.	1.9	14

#	ARTICLE	IF	CITATIONS
1466	Canakinumab in patients with COVID-19 and type 2 diabetes â€” A multicentre, randomised, double-blind, placebo-controlled trial. <i>EClinicalMedicine</i> , 2022, 53, 101649.	3.2	7
1467	Association of Serum Î³-Glutamyltransferase With C-Reactive Protein Levels in Patients With Coronary Heart Disease. <i>Angiology</i> , 0, , 000331972211210.	0.8	0
1468	Systematic Review and Meta-Analysis of Statin Use and Mortality, Intensive Care Unit Admission and Requirement for Mechanical Ventilation in COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2022, 11, 5454.	1.0	9
1469	Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations. <i>Molecular Therapy</i> , 2022, 30, 3106-3117.	3.7	23
1470	Red cell distribution width and Glasgow coma scale score as predictors of in-hospital mortality in maintenance hemodialysis patients diagnosed with spontaneous intracerebral hemorrhage. <i>Medicine (United States)</i> , 2022, 101, e31094.	0.4	3
1471	Importance of Intermittent Fasting Regimens and Selection of Adequate Therapy on Inflammation and Oxidative Stress in SARS-CoV-2 Infection. <i>Nutrients</i> , 2022, 14, 4299.	1.7	3
1472	Role of Sex in Atherosclerosis: Does Sex Matter?. <i>Current Cardiology Reports</i> , 2022, 24, 1791-1798.	1.3	5
1474	Nuevas estrategias en prevenciÃ³n cardiovascular. , 0, , 9-15.		7
1475	Relationship between the Hemoglobin-to-Red Cell Distribution Width Ratio and All-Cause Mortality in Septic Patients with Atrial Fibrillation: Based on Propensity Score Matching Method. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 400.	0.8	5
1476	Translational Molecular Imaging Tool of Vulnerable Carotid Plaque: Evaluate Effects of Statin Therapy on Plaque Inflammation and American Heart Associationâ€”Defined Risk Levels in Cuff-Implanted Apolipoprotein Eâ€”Deficient Mice. <i>Translational Stroke Research</i> , 2024, 15, 110-126.	2.3	0
1477	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1478	Effects of High- or Moderate-intensity Rosuvastatin on 1-year Major Adverse Cardiovascular Events Post-percutaneous Coronary Intervention. <i>Interventional Cardiology Review</i> , 0, 17, .	0.7	1
1479	Improvement of clinical outcomes in patients undergoing peritoneal dialysis using hydroxymethylglutaryl-CoA reductase inhibitors: A systematic review and meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 155-165.	0.6	0
1480	Statin Therapy for Cardiac Hypertrophy and Heart Failure. <i>Journal of Investigative Medicine</i> , 2004, 52, 248-253.	0.7	12
1481	Multifaceted role of cardiovascular biomarkers. <i>Indian Heart Journal</i> , 2023, 75, 91-97.	0.2	0
1482	The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. , 2023, 2, 122-164.		1
1483	The Cardiovascular Risks Associated with Aromatase Inhibitors, Tamoxifen, and GnRH Agonists in Women with Breast Cancer. <i>Current Atherosclerosis Reports</i> , 2023, 25, 145-154.	2.0	2
1484	A bidirectional Mendelian randomized study of classical blood lipids and venous thrombosis. <i>Scientific Reports</i> , 2023, 13, .	1.6	6

#	ARTICLE	IF	CITATIONS
1485	Lipoprotein (a), Inflammation, and Atherosclerosis. Journal of Clinical Medicine, 2023, 12, 2529.	1.0	7
1486	Frequency Of CRP Levels In Patients Presenting With Acute Coronary Syndrome. , 0, , 78-82.		0
1489	Anti-inflammatory Therapy for Cardiovascular Disease. , 2024, , 224-235.e1.		0
1493	High-Sensitivity C-Reactive Protein. , 2024, , 69-78.e2.		0
1494	Anti-inflammatory Therapy Progress in Major Adverse Cardiac Events after PCI: Chinese and Western Medicine. Chinese Journal of Integrative Medicine, 2023, 29, 655-664.	0.7	0
1495	Risikofaktoren und PrÄvention im Licht der Atherosklerose als Mikrozirkulationskrankheit. , 2023, , 81-102.		0